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SUMMARY
This research was aimed at increasing the yield of lymnno- 
blastoid interferon nroduced by the Namalwa line of lymphoblastoid 
cells. The parameters involved in the induction and production of 
interferon were studied first to give basic biochemical information 
about interferon and viral production in Namalwa cells. Optimised 
conditions were used for the remaining studies. The Namalwa cell line 
was cloned from single cells to determine whether there was any 
variation in interferon production in a population of cells. No 
significant variation was found so a study was made with cells treated 
with 5 ,_l>romodeoxyuridine and butyric acid. These chemicalB alter gene 
activity in many other cell types. The study was made using the 
mechanism of superinduction as a basic model for the control factors 
involved in interferon production. Neither chemical showed identical 
biochemical effects to the anti-metabolites used to effect super- 
induction in fibroblast cells. Thus it appears that the two chemicals 
act in a different manner to anti-metabolites. Neither compound 
affected the replication of the inducing virus, further investigation 
showed that 5'-bromodeoxyuridine required incorporation into cellular 
DNA before increased interferon yields were obtained. The effect of 
butyric acid on interferon yields could not be directly associated 
with any of its varied biochemical and morphological effects.
These results have increased out knowledge of lymnhoblastoid 
cells and indicated tkat interferon production in these cells may be 
controlled in a similar, though not identical way, to the model 
proposed for fibroblast interferon from fibroblasts. Two chemicals 
have been shown to increase the yield of interferon from Namalwa cells 
but the biochemical basis of their activity has not been resolved.
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1IgTBggggOg. - Its Biological properties.
Interferon was discovered by virtue of its ability to inhibit 
■viral growth in tissue culture ( Isaacs and Lindenmaan 1957 ) -  
Interferon is active in a wide variety of cells, both in vitro and 
in vivo, but appears to be species specific - thus human interferon 
is active on human cells but not on mouse or chick cells. The 
inhibition of viral growth in tissue culture cells required pre­
treatment of the cells with interferon before infection with virus 
for its maximum effect. Cells treated with interferon are resistant 
to infection by a wide variety of viruses and the oells are said to 
be in an 'antiviral state'. Few viruses are resistant to the actions 
of interferon»
Apart from the antiviral activity, interferon also exhibits 
effects on cellular funotions ( Dahl 1977 )• Firstly interferon oaa 
enhance or depress its own production in certain cells. These actions 
are termed 'priming' and 'blocld.ng' respectively ( Stewart, Cresser 
and Lockhart 1971»» 1971b ). Secondly interferon slows cell growth. 
This is referred to as the 'antioellular effect' ( Stewart et al 
1976 ). Cells vary in their sensitivity, and tumour cells are also 
sensitive to the 'antioellular effect'» Cells such as L1210 mouse 
leukaemia cells are inhibited in their growth in vitro, in their 
ability to form oolonies in agar and in their ability to form tumours 
in vivo ( Crasser ¿¿¿3k 1970, 1971 ). The antioellular effect has 
been observed with the most highly purified preparations of interferon 
and appears to be a real property of the moleoule. Interferon has 
also been shown to enhance the toxioity of the double-stranded RNA, 
poly(rl).poly(rC), for oells ( Stewart ¿¿¿1. 1972 ).
Interferon has at least two olinically useful properties - an 
antiviral effeot and an anti-tumour effect. Only human interferon will 
be of any potential use in man.
The potential olinioal use of interferon.
Tissue oulture studies show that interferon holds promise as a 
wide speotrum antiviral agent. Suoh an agent has long been sought
2after and. could be compared, to the wide spectrum antibiotics, like 
penicillin, which have had a big impact on disease. Furthermore, 
interferon has antitumour activity which may, or may not, be a 
result of its antiviral activity. Interferon is, however, in limited 
supply. The immediate targets for the olinical use of interferon 
are those infections that cannot be treated at present, such as 
viruses with many non cross-reactive serotypes (e.g. rhinoviruses), 
latent infections such as herpes simplex, where recurrent infections 
often occur, and chronic infections such as hepatitis B. The 
immediate effect of interferon should be to protect non-infected 
tissues and so prevent the spread of the virus. Thus in viral 
infections interferon must be given either early in infection or 
prophylactically to be of any use. It is anticipated that subsequent 
to the suppression of infection by interferon other normal body 
defences may overcome the infecting agent and effect a complete cure. 
At the present time it is impossible to treat prophylactioally with 
interferon beoause of the scarcity of the material.
Limitations on olinical use.
Interferon is produced i£ vivo in response to certain 
infections. In order to reach the levels of interferon seen in 
tissue in vivo, for the purpose of olinioal administration, it is 
naoessary to use large and frequent doses of exogenous interferon. 
Interferon is rapidly oleared from the bloodstream after injection, 
though its fate is not known and it is inactivated by many body 
fluids. The doses normally given are more than 10^ units of
interferon per patient, per day, for the systemio infections. The
8 9activity of interferon appears to be in the region: of 10 - 10 
«Hits per milligramme and thus this kind of dose is equivalent to 
about 10 miorogrammes (see Pollard and Merigan 1979)»
The usage of interferon is restrioted by the small amounts of 
interferon that are made by oell cultures (up to about 10^ units/ 
millilitre) and the very small proportion that interferon represents 
of the total protein in the preparations. This means that relatively 
large soale handling is required and the subsequent purification of
3interferon is difficult. The majority of the interferon used 
clinically is made from leukocytes isolated from whole hlood 
( Cantell 1978 ). About 1011 units of interferon can he made per 
year. Thus relatively few patients cam he treated at present, 
particularly where long term trials are required. This interferom 
has heen successfully used to treat osteosarcoma patients in 
Sweden ( Strander et al 1973 ). The purity of these preparations 
has reoently reached about 5 1 10^ per milligramme or about 1#
( Cantell and Hirvonen 1978 )• However, there do not appear to be 
any severe side reactions caused by the impurities to date ( Pollard 
and Merigan 1979 )•
The immediate possibilities for increasing production of 
interferon must lie with much larger scale handling, continuous 
culture production, the use of high producing cells, or indeed a 
combination of these factors.
In the long term interferon provides a prime target for 
genetic manipulation. The subsequent production of interferon in 
bacteria could achieve higher production, both by virtue of the 
higher cell densities that oan be achieved and the conversion of a 
large proportion of cellular synthetic activity to interferon 
production. The latter can be achieved by the insertion of many 
copies of the interferon gene into the oell.
The antiviral activity of interferon.
Two approaches that could potentially increase the avail­
ability of interferon for olinioal use oan be oonoeived. Either the 
amount of interferon per culture of cells oould be increased, as 
indicated above, or the antiviral activity of interferon oould be 
inoreased.
Increases in the effeotive antiviral concentration of 
interferon can be produoed either by altering the protein itself, 
or by inoreasing the speoifioity of the interaction of interferon 
with the target tissue.
4The interferon receptor.
It is known that interferon must he externalised from the 
producing cell before it is aotive ( Vengris, Stollar and Pitha 
1975 ). This could simply result from its compartmentalisation 
within the cell (see later). However, there is an interaction 
at the cell surface which involves a cellular reoeptor of some 
kind ( Chany et al 1975» Slate and Huddle 1978 ). Presumably some 
oells are not sensitive to interferon because they do not possess 
these receptors. An increase in the number of receptors per cell 
may increase the sensitivity of the cells to the effects of 
interferon. Receptors of differing affinities have been proposed 
to account for the differing interactions of different species of 
interferon on the same kind of cell ( Edy, Billiau and DeSomer 
1976, Gardener and Vilcek 1979 )» Since the structure of interferon 
may soon be known ( Weissenbach et al 1979 ) a knowledge of the 
structure of these receptors might allow the synthesis of more 
specific "interferons" by chemical modifications of purified 
interferon to give a more specific interaction. It is assumed that 
the interferon-receptor interaction is similar to the hormone- 
receptor systems that have been well characterised. Polypeptide 
hormones such as insulin use a 'secondary messenger' as an 
amplification system ( Butcher, Robinson and Sutherland 1972 )«.
It is jiot known if interferon requires a second messenger or how 
many moleoules of interferon are required to induce the antiviral 
state. Both insulin and interferon ( Greaser 1977 ) are known to 
have many effects on the oell surface including alterations of 
transport of certain moleoules into the cell.
Liposomes offer a potentially useful delivery system for both 
interferon itself ( La Bonnardiere 1979 ) or for the interferon 
inducers such as poly(rl).poly(xC) ( Magee e£ .ai, 1976 )- As yet 
they laok the tissue speoifioity that would be required to give 
very localised high concentrations of interferon but they do offer 
protection to the messenger moleoules from inactivation*
5The antiviral mechanism.
The mode of inhibition of viral replication by interferon 
is not well understood. There is evidence that viral replication 
can be inhibited at three sites - transcription, translation and 
maturation. The first observation of an inhibition of primary 
transcription was vesicular stomatitis virus (VSV) ( Marcus et al 
1971 )• The most convincing studies in this area are those done on 
simian virus type 40 ( Oxman and Levin 1971, Metz, Levin and 
Oxman 1976 ). It appears that the inhibition of primary transcription 
is not enough to account for the marked inhibition of viral 
replication.
Inhibition of viral translation has been observed in intact cells 
and in cell-free systems. For VSV and reovirus it has been shown that 
only a slight transcription inhibition occurs so that an inhibition 
of translation may occur ( Yamamoto, Yamaguchi and Oda 1975»
Wiebe and Joklik 1975 )• The cell may discriminate between viral 
messenger RNA (mRNA) whose translation is inhibited, and cellular 
mRNA, which is not inhibited, by making modified cellular mRNA*s 
that are larger than normal ( Levy and Hiley 1973 ). In cell-free 
systems a low molecular weight inhibitor of translation has recently 
been identified as a novel Oligonucleotide ( Kerr and Brown 1978,
Ball and White 1978 ). This oligonucleotide has also been 3hown to 
activate an endonuclease ( Clemens and Williams 1978 ). The 
selective phosphorylation of two proteins occurs in the presence 
of ATP. They have molecular weights of 67,000 and 35,000. The 
latter may be one of the eukaryotic initiation factors eIF-2, 
which is required for initiation of protein synthesis ( Revel 1977 )• 
The activation of all these components requires interferon pre- 
treatment of intact cells and the addition of double-stranded RNA 
to the cell-free system made from the cells. Double-stranded RNA 
is thus suggested to cause the activation of three 'enzyme presursors' 
which are converted to a specific kinase, an endonuclease and the 
oligonucleotide synthetase ( Baglioni 1979 )• However, it appears 
that the latter enzyme is made de novo and requires transcription 
before it is observed in interferon treated cells ( Ball 1979 )»
6while neither the activation nor the activity of the endonuclease 
requires protein synthesis ( Satner et, a¿ 1977» Taquero and Clemens 
1979 )• Furthermore, a new protein of 56,000 molecular weight is 
observed. While the oligoadenylate synthetase activity oopurifies 
with this protein, the two have not been shown to be identical 
( Ball 1979 ). ( It is interesting to note that this is the first 
olear evidence that gene activity is controlled by interferon 
treatment. ) The specificity of the resulting inhibition of 
translation by these faotors remain to be shown.
This system is not restricted to the interferon induced antiviral 
state. The production of the three moleoules found in interferon 
treated oell extracts also occurs in crude rabbit retioulooyte 
lysates in the absence of interferon treatment, but in response to 
double-stranded RNA ( Farrell et al 1977, Taquero and Clemens 1979 )• 
They are also found in L cells ( Clemens and Williams 1978 )•
Addition of purified eXF-2 in the retioulooyte system does not 
overoome the inhibition of translation, whereas the additiomof 
new mRNA does. This suggests that the endonuclease activity is the 
important factor in the inhibition of the translation ( Taquero and 
Clemens 1979 )« The oligoadenylate varies with the hormone (oestrogen) 
status of the tissue ( Start et al 1979 )* Thus the oligoadenylate 
and its associated endonuolease may represent a mechanism for degrad­
ing cellular mBHA's in preparation for assuming specialised functions 
and particularly these moleoules may regulate tissue regression and 
differentiation ( Hovanessian and Kerr 1978, Stark et al 1979 )•
Recent evidence suggests that interferon can .also inhibit 
certain viruses at the stage of maturation and release. ENA tumour 
viruses such as murine leukaemia virus ( Billiau et al 1974, 1975) 
Friedman and Ramaeur 1974, Friedman 1975 and Pitha $ 1 ¿1 1976 ),
mouse mammary tumour virus ( Wong al 1977 and Chang al 1977 ) 
and ST5 ( Billiau ¿ i  1978 ) appear to be inhibited at this stage. 
Such an inhibition is not restricted to RNA tumour viruses sinos TST 
partióles with low infeotivity are made in interferon treated oells 
and there is a preferential inhibition of the release of infectious 
partióles ( Naheshwari and Friedman 1979 )• The partióles only oontain 
full genomes and are not thus defeotive. Interferon alters the viriom
7structural component (s) or changes the properties of the cell plasma 
membrane. Changes in the cell membrane have been observed after 
interferon treatment ( Lindahl st al 1973» Vengris ejt al 1976 and 
Chang et. al 1978 ).
It thus appears that the interferon mediated inhibition of 
viral replication does not have a single mechanism but several, 
possibly to oope with the wide variety of viruses.
The antiviral meohanism seems to use oellular regulatory 
moleoules that are not interferon specific. Thus, at present, there 
does not appear to be any specifically modifiable system that would 
allow an increase in the antiviral activity to be realised. The 
meohanism of the induction of the antiviral state is not known so 
neither can this stage be controlled. Thus the best possibility of 
realising the potential olinical use of interferon is to make higher 
specifio activity preparations.
To this end I shall outsider what is known about the regulation 
of interferon production. It is not possible to exhaustively review 
all the data here, and there are many recent reviews of this kind in 
any oase. Therefore I shall confine myself to the key ideas that 
offer the potential for increasing the yields of interferon fro» cells.
Firstly, then, let me consider the nature of interferon since 
an understanding of this suggests the type of control by which the 
noleoule is likely to be regulated.
The patuye of Ifllertprop p o p p l e .
Interferon is a protein and is probably glyoosylated ( Mail 
and Dorner 1973 ). The molecular weight of interferon is not 
preeisely known but appears to be in the region of 20,000. 
Determination of the moleoular weight is difficult beoanse glyco­
proteins behave aberrantly on polyacrylamide gels and because there 
are several biologioally active moleoular sizes, that behave as 
interferons, in interferon preparations. This latter effeot is 
called 'microheterogeneity1 and may arise as a result of three 
posslbilitiee. Either interferon is bound to a range of other 
proteins, or it has differing amounts of oarbohydrate residues
8per molecule, or -there is more than one protein sequence that 
possesses antiviral activity. There is evidence that each of these 
possibilités occurs and accounts for the 'microheterogeneity' 
observed for interferon.
Purification of interferon from orude preparations removes the 
contaminating proteins and reduces, to some extent, the microhetero— 
geneity. Interferon is sow known to bind to a range of proteins 
suoh as bovine serum albumin with a high affinity and such binding 
properties have been exploited as a method for purifying interferon 
( Huang ,et al 1974 )•
Interferon is also present in forms that differ in their 
amount of glycosylation. Preparations can be treated in vitro with 
glycosidases. This treatment reduces the number of species of 
interferon deteotable ( Bose et al 1976 )• Periodate can also be used 
to specifically remove carbohydrate residues, although this agent 
can attach amino acids and the resulting activity of the interferon 
preparation is low ( Stewart et al 1977 ). In the intact cell 
inhibitors of glycosylation have been used ( Havell et al 1975 > 
Mizrahi et al 1978 and Fujisawa, Ikwaknra and Kawade 1978 ). All 
these treatments show that some of the mioroheterogeneity of 
interferon preparations seem to be due to differing extents of 
glyoosylation. Although it cannot be proven that a few carbohydrate 
residues remain on the protein after these treatments, it seems that 
the non-glyoosylatsd interferon retains activity. Thus the 
carbohydrate residues do not seem to be required for biological 
activity. The biologioal significance of glycosylation is not yet 
known for any protein ( Kornfeld and Komfeld 1976 ). It has, 
however, been suggested that glyoosylation particularly the 
presenoe of sialic acid residues, may protect the protein against 
degradation ( Dorner, Soriba and Weill 1973 ). The fact that 
interferon is a glyooprotein may aooount for the fact that it 
penetrates poorly into tissues after injeotion.
Hot all the mioroheterogeneity oan be removed using the methods 
above, and there is evidenoe to suggest that interferon activity is 
associated with more than one protein primary sequenoe. Interferons 
from different speoies can be distinguished antigenioally, so the
primary sequence does not appear to be highly conserved as a whole. 
Human interferons can also he sub-classed antigenically. There 
appear to be three types of human interferon by this criterion. At 
least two of these types are made in different cells. Fibroblasts 
make human fibroblast interferon (HFIF) and leukocytes make human 
leukocyte interferon (ELeXF). These interferons can be used to 
proteot the same kind of cells but one type is generally more 
active than the other on a given cell type ( Edy e£ al 1976 and 
Gardener and Vilcek 1979 )•
Human interferon also demonstrates some deviation from what was 
considered a general property of interferons — that of species 
specificity. HLelF is active in bovine and feline cells, sometimes 
more active than on human cells, whereas HFIF is not aetive in these 
cell types ( Gresser at al 1974» Desmyter and Stewart 1976 and Edy 
et al 1977 )• This is not a property confined to human interferon 
but it does appear that interferons have a restricted host range in 
terms of aotivity ( Stewart 1979 )•
Direct evidence that there are at least two structural genes 
for interferon comes from studies on an human lymphoblastoid oell 
line. These cells produce interferon that is mostly HLelF, but a 
small proportion of the antiviral activity is not precipitated by 
anti-HLelF antibody but is precipitated by anti-HFIF antibody and 
thus appears to be HFIF ( Pancker 1977 and Have 11, Tip and Tilcek 
1978 ). Both types of interferon are also made if interferon messenger 
ENA is eztraoted from these cells and translated in Xenonus oocytes. 
The interferon made in the oocytes shows the same proportion of the 
two types of interferon as made by the intact lymphoblastoid oells.
It is unlikely that the oooyte has two different glyoosylation 
systems for a single protein and therefore this result suggests that 
the two interferons are structurally different ( Cavalieri ¿t al 
1977 )• Thus some of the heterogeneity of interferon preparations 
may not result solely from differences in glyoosylation.
A third type of human interferon is known that has all the 
properties of an interferon ( see Lookhart 1966 ) except that it 
is unstable at pH 2 and produoed in response to different inducers 
( see later ). This interferon is antigenioally different from the
other two human interferons which are stable at pH 2 ( Valle et. al 
1975 )•• The pH 2 stable species are referred to as Type I interferons 
and the pH 2 unstable interferon as Type IX. Type II interferons are 
also found in other species and can be identified both in vitro and 
in vivo. It is not known which lymphoid oell type produces Type II 
interferon. The existence of human Type II interferon implies, but 
does not prove, that there are at least three human structural genes 
for interferon. Another possibility is that splicing occurs within 
a single gene.
An important point to bear in mind when interpreting the data 
is that the antisera used are not raised against purified interferons. 
This is because there is insufficient pure interferon to use. Thus 
the antigen(s) involved in the precipitation reactions are not 
precisely known.
The genetics of the interferon system.
It has previously been indicated that there are probably at 
least three structural genes for human interferon. Extensive work 
has been undertaken both i£ vitro and in vivo. All the methods 
rely on the assumption that the yield of interferon is direotly 
related to the genotype. As pointed out above, variations can occur 
that are not thus related.
Two approaches have been taken in vitro. The production of 
somatio oell hybrids by fusion is the major tool. Theme hybrids 
preferentially lose chromosomes from one of the parent oell types.
Thus mouse-human hybrids retain only a few human ohromoaomes. This 
process is oontinual so there is a problem with the stability of the 
karyotype in these experiments. The first hybrids were made between 
nucleated chiok erythrocytes and two human oell lines. Of the three 
parental oell lines only one of the human oell lines made interferon. 
When this interferon produoer was fused with the ohiolc oell the 
resultant hybrid made both human and ohiok interferons. The non- 
produoing human line when fused made no interferon at all 
( Guggenheim, Friedman and Babson 1968 ). Enhanced expression of 
interferon genes thus presents a possibility for making high
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producers. This has been achieved with human-hamster ( Morgan and 
Faik 1977 ) and mouse-hamster ( Carver, Seto and Midgeon 1968,
Smith and Sedak 1975 )• For the former set of hybrids human chromo­
some 18 controls the production of hamster interferon.
Chromosome assignments for human fibroblast interferon have 
suggested that two genes are required for production. These loci 
are situated on chromosomes 2 and 5 ( Tan 1977 )• Interferon 
production in hamster-human hybrids provides evidence that the 
structural gene locus is on chromosome 5 and chromosome 2 contains 
a regulatory locus. Recent evidence conflicts with these data and 
suggests that chromosome 9 is solely required for the expression of 
interferon ( Meager et al 1979 )•
Aneuploid cells have been used to study gene dosage effects 
i.e. by comparing cell lines having varying numbers of copies of 
oertain chromosomes or partial deletions of chromosomes. The data 
show that the long-arm of chromosome 5 has the structural gene 
locus while the short-arm has a  locus for the repressor or similar 
regulatory function ( Tan 1977 )• High producing cell lines have been 
seleoted by cloning out cells containing multiple oopies of 
chromosome 5» and these have been used to provide good material 
which can be purified to homogeneity ( Berthold et al 1978 )•
Studies ia vivo have been restricted to mice where two loci 
determining interferon production have been identified. Different 
loci were subsequently identified for different induoers ( DeMaeyer 
at ai 1974 ).
Qeneral consideration of the regulation of the interferon system.
Interferon is an inducible protein. Inducible proteins are 
specialised proteins whose synthesis is not normally required by the 
oell. The dlassio example of an inducible system is the/^-galaoto- 
sidase gene studied in B. ooll./^  -galactosidase is not normally 
made until the oell enoounters lactose as a source of carbon and 
energy. Work on this system resulted in the operon model for 
regulation at the level of tbs DMA ( Jacob and Nonod 1961 )- 
Other examples whioh oonform to this hypothssis are found in
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prokaryotes but evidence is lacking to support this hypothesis 
in eukaryotes. Many inducible systems are found in eukaryotes, 
some for one or a few proteins such as the interferon system and 
others giving rise to larger scale changes in hiosynthetio activity 
within cells, such as those processes under hormonal control e.g. 
progesterone/oestrogen ( O'Malley et al 1969 ) or those falling 
into the broad category of differentiation ( Eutter ert al 1973 ).
In all these eases there is de novo synthesis of new mENA's.
Induction of protein essential to the cell also occurs. One 
example is the induotion of tyrosine aminotransferase (TAT) 
aotivity above basal level by oortisone ( Tomkins et al 1966 ).
In this oase there is no evidence that there is any increase in 
the levels of TAT mBHA.
The interferon induoer.
The inducer for interferon oan be one of many substances. The 
most common inducers are viruses and the synthetic double-stranded 
ENA poly(rl).poly(rC). Typell interferon can be stimulated by many 
diverse molecules including bacterial endotoxins and several low 
molecular weight moleoules — for a comprehensive list of induoers 
see Kleinaohmidt (1972)«
Hot all oells oan be induced for interferon and furthermore 
not all potential interferon producing cells respond to all inducers. 
Particular oell lines do not give rise to the same yields of interferon, 
when compared to other oell lines or the effect of different induoers- 
fields oan vary with differing preparations of a single induoer and 
with the oulture conditions of the produoing oells. The prooesses 
behind these variations are not known, though some of the possibilities 
have been put forward ( see Stewart 1979» page 80 ).
If large scale production of interferon oan be achieved then 
it is obviously important to oontrol these variations. The 
unravelling of the prooesses that regulate interferon produotion 
would allow muoh better oontrol of yields.
The role of the induoer,
The interaction of cells with the inducer is not understood.
The steps involved in triggering interferon production are unknown..
In the case of poly(rl).poly(rC) induction the site of induction 
has still to he resolved ( Pitha and Piths 1973 )• It is generally 
accepted that induction involves the derepression of the interferon 
gene(s). How this event is connected, if at all, with the various 
effects of douhle-stranded HNA —  the postulated inducer — which occur- 
concurrently with the induction is not known ( Torrence and 
Friedman 1979 )•
Other phenomena assooiated with induction are priming and 
hyporeactivity. Priming occurs after pretreating oells with low 
doses of interferon resulting in higher titres after induction 
than normal. The mechanism underlying priming is not understood 
hut it appears that the cells heoome more sensitive to double- 
stranded RNA ( Kerr et al 1974 )• Priming does not occur if the 
interferon treatment is given at the same time or later than the 
inducer. Pretreatment with interferon is thus required. This also 
alters the membrane properties of oells so priming could possibly 
be associated with an increased uptake of inducer, which presumably 
has a membrane receptor.
Hyporeactivity is a diminished interferon response to an 
induoer whioh can ocour very- quickly after induotion ( Breinig, 
Armstrong and Ho 1975 )• Thu* it seems unlikely that interferon 
itself is involved in this phenomena. However, in view of the 
persistence of the effeot it also seems unlikely that the induoer 
per se is involved.
The production of interferon after induotion.
Once induoed the rate of interferon production reaches a maximum 
in a matter of hours and then declines again to undeoteotable levels. 
This corresponds to the situation described by the Jaoob and Nonod 
model but is unlike terminal differentiation, an example of which 
is the induotion of haemoglobin synthesis In erythrocytes, where
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haemoglobin?, synthesis is not switched off. The kinetics of interferon 
production varies with the cell type and the inducer ( Stewart 1979 )• 
Priming seems to shorten the period after induction during which 
interferon is undetectable ( Fleischman 1977 )*•
Treatment of the producing cells with antimetabolites during 
induction and interferon production originally showed that interferon 
is made de novo and has a messenger RNA. The use of particular dual 
regimens, e.g. actinomyoin D and cyoloheximide ( Tan et ad 1970 ), 
gpve paradoxical results - interferon yields were actually increased. 
This phenomena is oalled 'superinduotion'.The kinetics of interferon 
production show an earlier detectable response to the induoer and a 
longer period of interferon production ( Vilcek and Kohase 1977 )«
Not all cells can be superinduced, though the reason is not known. 
Priming and superinduotion are sometimes synergistio. Superinduotion 
has only been observed when using poly(rl).poly(rC) or Ultra-violet 
irradiated Newcastle Disease virus. Ultra-violet irradiation of the 
oells before induction can also result in superinduotion ( Vilcek, 
Have11 and Kohase 1976 ).
Beoently it has been reported that other agents can alter the 
interferon yields from oells. Both S'-bromodeoxy jridine —  an 
analogue of the DBA. preoursor thymidine — ( Tovey e£ al 1977 ) 
and sodium butyrate — a short ohain fatty acid - ( Johnston et. al 
1979 ) can inorease yields of interferon, while retinoio acid - a 
vitamin A derivative — inhibits interferon production ( Blalook and 
Gifford 1976 )-
The interferon system departs from the y^-galaotosidase system 
in that interferon oannot be produoed continually in the presence of 
induoer. If further inducer is added after the initial production has 
oooured then little or no further interferon is produoed by the oell 
( Viloek 1962 and Vilcek and Bada 1962 ). Cells do not reoover from 
this hyporeactive state for a period usually of several days after 
interferon production has oooured ( Breinig, Armstrong and Ho 1975 )• 
The prooesses that result in hyporeactivity are not known.
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Interferon is a cellular glycoprotein which, must he induced 
before synthesis takes place. Interferon is made by translation of 
a specific mENA. The extent of translation is controlled by a shut 
off mechanism which prevents continuous production and further 
induction. However the use of certain agents can increase interferon 
yields.
The selection of high producing cell lines could be achieved in 
one or more of the following ways.
The selection of a highly efficacious inducer would endure that 
all cells were produoing interferon and at their normal maximum rate. 
Studies on the nature of the inducer could lead to the selection or 
synthesis of more aotive or effeotive inducers«
Isolation and amplification of the structural gene(s) for 
interferon using genetic manipulations could provide increased 
yields of interferon per cell.
The rate of transcription of the interferon gene to give 
interferon mENA could be increased. This could include a change 
in the rate of processing of a precursor ENA which represents the 
primary transoript.
The rate or period of translation might be increased. This 
oould be achieved either by increasing the amount of functional 
interferon mENA, as above, or by altering the efficiency of 
translation* The latter oould result from an increase in the 
competition of interferon mENA for ribosomal binding sites 
oompared to other messenger BNA's or by increasing the rates of 
the initiation, elongation and termination of the polypeptide chain.
Changing the rate or extent of post translational modification 
or secretion may also permit higher extra oellular levels of 
interferon to be achieved.
I shall now consider what is known about these possible 
regulatory sites, as far as the interferon system is conoemed, 
in more detail.
16
The regulatory sites in interferon production.
The nature of the inducer.
The identity of the inducing molecule has been studied 
extensively. At first sight the sheer diversity of the types of 
inducers does not present an obvious candidate for the inducing 
molecule. The inducers known to date have been variously classified. 
Grossberg (1977) has listed the following classes»
Type 1 inducers.
Viruses.
Double stranded SNA's - synthetic and animal cell derived.
Intracellular microbes..
Microbial products.
Chemicals - polymers and low molecular weight compounds.
Type 11 inducers.
Antigens - in sensitized immunocytes..
Mitogens - 'TT and lymphocytes.
For Type 1 inducers it has been suggested that double stranded 
RNA is the inducing component ( Kleinschmidt 1972 ). Negative 
stranded viruses, such as Newcastle Disease virus (NDV), are potent 
inducers. Such single stranded SNA viruses form double stranded 
replicative intermediates synthesized by the virion associated RNA 
dependent HNA polymerase ( Field et al 1967 )• Ultraviolet Irradiated 
NDV(UV-NDVT) is a more potent inducer than the wild type virus, 
although it is unable to replicate ( Ho and Breinig 1965 )• UV-NDV 
still has HNA dependent RNA polymerase activity and produces base- 
paired HNA both in vitro and in vivo ( Clavell and Bratt 1971 )«
The synthetic double stranded HNA poly(rJ).poly(rC) is a well 
known inducer and the structural requirements for induction have 
been exhaustively tested ( Levy 1977 )• Reovirus, which contains 
double stranded RNA segments in the intact viriom is also an induoer.
Vaccinia virus, which is a DNA containing virus, both induces 
interferon and forms a double—stranded SNA replicative intermediate. 
Of the non double-stranded RNA inducers some of the fungal inducers 
such as statolon have either associated mycophages containing double- 
stranded BHA, or have other associated BHA.
The case against double—stranded BNA has also been put. Double- 
stranded BHA from intact non interferon producing cells can be 
isolated and used to induce other cells ( DeMaeyer et, al 1971 and 
Kimball and Duesberg 1971 )*• Other studies have shown either no 
correlation between the amount of double-stranded BHA produced by 
an inducer and its inducing ability ( Lockart et al 1968, Thacore 
and Tounger 1970 and Meager and Burke 1972 ) or even an inverse 
correlation ( Lomniczi and Burke 1970 ). Vaccinia virus double- 
stranded BHA will not induce interferon in chick cells either 
( Bakay and Burke 1972 ). This has led some people to suggest that 
other viral functions are required for induction ( Gauntt 1973»
Lai and Joklik 1973, Atkins and Lancashire 1976 and Kowal and Tounger 
1978 )» Other non double-stranded BHA inducers do not give rise to 
interferon in whols animals —  only in tissue culture cells. It has 
been suggested that these agents may act by perturbing the immune 
system, to which the interferon system is olosely linked ( Grosser 
1977 ).
The most elegant demonstration of the role of double-stranded 
BHA in interferon inductions oome from the use of defective mutants 
of VSV ( Marcus and Sekelliok 1977 )• One such mutant ( +VSV ) 
consists of a double-strand of complementary BHA representing both 
message and virion sense BHA covalently linked together to form a 
hairpixn structure. In the absenoe of detectable transorlption from 
this BHA it was found that a single molecule per oell of this 
+VSV mutant was required for interferon induction.
Thus it seems that if a unifying hypothesis can be formulated, 
double—stranded BHA is the most likely candidate moleoule to be 
oast in the role of the induoar.
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Assays for the interferon messenger SNA.
Early work with Metabolic inhibitors showed that both SNA 
synthesis ( Heller 1963, Wagner and Huang 1965» Field et al 1967 
and Seghal, Tamm and Vilcek 1975 ) and protein synthesis ( Tan, 
Armstrong and Ho 1971 ) was required for interferon production and 
that interferon was itself sensitive to proteases. This suggested 
that interferon is a protein and has a messenger RNA.
The interferon system has few structural genes. Thus any 
measurement of transcription of the interferon gene(s) requires 
a very specific and sensitive assay. Potentially the most sensitive 
assay for messenger RNA (mRNA) results from the use of a highly 
labelled and speoific probe. This probe can be made from the purified 
mHNA using the enzyme reverse transcriptase and labelled deoxynucleo- 
tidge. A complementary SNA (cSNA) is thus synthesized which will 
specifically hybridise to any RNA oarrying the mRNA sequences. This 
thus allows the primary transcription products to be assayed regardless 
of any post—transcriptional modification such as processing and 
degradation. For the interferon system it has not been possible to 
purify the interferon mHNA. Therefore the approach described above 
oannot be taken.
The assays used to date aret cell-free translation, heterologous 
oell systems and microinjeotion of Xenouus oocytes. Only interferon 
that is translated in these systems to give biologically active 
interferon can at present be identified. This RNA may not represent 
the primary transcript. Thus comparisons of interferon mRNA levels 
between different oell types is qualitative since they rely on the 
producing systems making reoognisable interferon mRNA and have 
associated problems of nuolease activity, competition with other 
mRNA's both from the producing and assaying oells, and the 
possibility that differing post-translational modification and 
degradation will alter the final titre of interferon obtained.
The first system used to measure interferon mRNA was the 
heterologous oell system ( DeNaeyer-Ouignard 1972 ). Messenger
RNA preparations oan be added to tissue culture oells and these oells
produce active interferon that has the same species specificity 
and antigenic properties of interferom made in the producing cell 
from which the mRNA was isolated. Interferon characteristic of the 
assay cell is not produced. The mRHA is apparently absorbed by the 
cell. The ability of DEAE-dextran to increase the sensitivity of 
the assay ( Kronenberg and Friedman 1975 ) is consistent with the 
idea that it increases the absorption of SNA by cells ( Tovell and 
Colter 1967 ). It is likely that only a small proportion of the 
mRNA activity added to the cells is assayed and differential 
absorption is a possible problem with this assay from a Quantitative 
point of view..
Cell-free translation systems have been used to obtain similar 
results ( Pestka e¿ al 1975» 2aj and Pitha 1975 and. Thang et al 1975 )> 
see also page 28 .
Xenoous oocytes have also been used ( Reynolds, Premkumar and 
Pitha 1975» Cavalieri et al 1979 and Morser e£ ¿1 1979 )• This system 
has certain advantages. Only about 1% of the RNA required for cell- 
free translation gives comparable synthesis and post translational 
modifications can be carried out in the oocyte. Post—translational 
modifications may be required to give biologically active interferon. 
However there are disadvantages. One is the microinjection technique 
require* to put RNA into the cell. RNA may consequently not enter the 
cell or leak out after the injectiogr. The method of selection is not 
known and neither is it known if all mRNA's are translated with equal 
efficiency. The titre of interferon produced thus depends on 
competition between interferon mRNA and other cellular RNA's that 
are coinjected and the oocyte's own mRNA's.
These assays have shown, invariably, that non-induced cells do 
not contain translatable interferon mRNA.. It is not possible to 
completely rule out two possibilities - namely that interferon mRNA 
is present in an inactive form in uninduced cells with the inducer 
bringing about its activation, or that interferon mRNA is constituitively 
made but rapidly degraded in uninduced cells ( Vilcek and Xohase 1977 )•
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Superinduction - a oost-transcriptional event ?
It is possible to alter the amount of interferon made in certain cell 
types- The interferon yield can be depressed or increased according 
to the treatment used.. It is interesting to note that interferon 
itself can both increase and depress its own synthesis depending on 
the dose used for pretreating the cells ( Stewart, Lockhart and 
Grosser 1971a, 1971b ). There is no evidence to suggest that these 
alterations arise from any change in the induction requirements 
or post-translational events. The evidence does suggest that both 
amounts of transcription and translation are altered. Direct evidence 
for an increased amount of transcription has been obtained by assaying 
the amount of interferon mRNA made- An increased amount of interferon 
mENA has been reported in cells pretreated before induction with 
5'-bromodeoxyuridine and butyric acid ( Morser et al_ , unpublished ) 
and from superinduced cells ( Seghal et al 1977» Reynolds, Prekumar 
and Pitha 1975 and. Cavalieri et al 1979 ). In the latter case it 
seems that the increased transcription is $ot enough to account for 
the increase in yields of interferon made in intact cells ( Raj and 
Pitha 1977 and Cavalieri et al_ 1977^ )•• Cycloheximide alone has also 
bBen reported to superinduce cells ( Seghal, Dobberstein and Tamm 
1977 )» These data suggest that superinduction is, at least in part, 
accounted for by increased translation. Priming cells with interferoni 
gives rise to higher yields of interferon in response to an inducer 
without a detectable increase in transcription ( Abreu, Bancroft 
and Stewart 1979 )• The production of interferon does however 
parrallel the amount of interferon mRNA detected in cells ( Seghal 
et al 1977 ) suggesting that events prior to translation: are rate 
limiting.
Two studies have shown that post-transcriptional modification 
of interferon mRNA occurs. It is known that interferon production 
declines to undetectable levels after reaching a peak rate. One 
reason for this could be that the interferon mRNA has a short half- 
life- It has been shown however that interferon mRNA is stable afta? 
injection into oocytes ( Seghal, Lyles and Tamm 197& and Colraan 
and Morser 1979 ) and in metabolically blocked PS-4 cells ( 3eghal,
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Tamm and. Vilcek 1975 )> for several days. In the latter case the 
metabolic block can be reversed since both 5»6-dichloro-l -Â-V- 
ribofuranosylbenzimadazole (DRB)- which inhibits RNA synthesis - and 
cycloheximide - a protein synthesis inhibitor - can be washed out.
If this is done the rate of interferon production by the FS-4 cells 
rapidly declines to zero.
Alterations in the transcriptional modification of interferon 
mRNA have been proposed as a mechanism to account for the superinduation 
phenomena. Superinduction occurs in many systems and with a wide 
variety of metabolic inhibitors ( Tomkins et al 1972, Chatterjee 1979 )■> 
Three hypotheses have been put forward to account for superinduction. 
These are inhibition of degradation of the mRNA, a decreased 
competition for translation of the mRNA on polyribosomes, or an 
inhibition of inactivation of the mRNA*
In hepatoma cells superinduction of the enzyme tyrosine amino 
transaminase (TAT) is known. It is proposed that the levels of this 
and other intracellular enzymes must be tightly regulated. This may 
be achieved by having rapidly turning over mRNA's for these enzymes. 
Serunr. and insulin slow the enhanced degradation of TAT mRNA that 
occurs in growth inhibited cells* This results in a rise in. the 
specific activity of TAT without a change in the rate of synthesis 
of the mRNA. Actinomyoin D superinduces TAT in these cells and is 
thought to act by inhibiting degradation: of TAT mRNA ( Steinberg, 
Levinson and Tomkins 1975 )•
It seems unlikely that interferon mRNA would be regulated 
in this manner since interferon is actively exported from the cell 
( Tan,Jeng and Ho 1972 ), and not constituitively made.
Ovalbumin can also be superinduced by actinomyoln I) ( Rhoads, 
McKnight and Schimke 1973 )• It is suggested that actinomyain D 
inhibits RNA synthesis as its primary site of action. This means 
that less stable cellular RNA's will be degraded faster than stable 
mRNA's. If ovalbumin mRNA is stable then there will be less competition: 
for polyribosotaes with time since the total mRNA ¡population has 
declined. Thus a more efficient translation of stable mRNA's on 
polyribosomes will result, giving increased production of their 
protein products*
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la the interferon system, actinomycin D treatment alone does 
not superinduce interferon ( Tan and Berthold 1977 ). The fact that 
a number of inhibitors can be used to obtain superinduction ( Tan 
ejt al 1970, Vilcek and Ng 1971> 3eghal and Tamm 1975» Tan and 
Berthold 1977 ) supports the idea that the primary site of action 
of these inhibitors is a general inhibition of RNA and protein 
synthesis» 5his is in spite of the observations that certain: 
inhibitors are not as specific as was at first thought. Per instance, 
actinomycin D is used as an inhibitor of RNA synthesis but it has 
been shewn to affect translation in vitro ( Leinward and Ruddle 
1977 ). -he concentrations of both actinomycin D and cycloheximide 
used to give superinduction are also above those required for optimal 
inhibition of RNA and protein synthesis ( Seghal, Tamm and Vilcek 
1976 ). Superinduction can also be achieved with DRB and 
cycloheximide. DRB has been shown to inhibit mRNA synthesis including 
interferon mRNA ( Seghal, Tamm and Vilcek 1976 )» Therefore it is 
not a preferential inhibition of other classes of mRNA leading to 
decreased competition of interferon mRNA for polyribosomes that 
account for the superinduction of interferon» If the DRB treatment 
is delayed until late in the 'shut-off' phase of interferon, 
production, then interferon production declines for a further 3-4 
hours and then stabilises for a prolonged period. If the interferon 
mRNA was simply displaced from the polyrobosomes during the 'shut-off' 
phase then it would be expected that a rise in interferon production 
would eventually be seen after such DRB treatment ( Seghal and Tamm 
1976 ). Furthermore, no translatable interferon mRNA can be extracted 
from cells that is not present on polyribosomes ( Seghal, Dobberstein 
and Tamm 1977 )• Thus it seems that a simple competition model 
will not suffice to explain interferon superinduction»
Lastly it has been suggested that a repressor system operates 
which inactivates specific mRNA ( McAuslan 1963 )• It is proposed 
that antimetabolites differentially inhibit the formation of this 
repressor ( Tan _et ¿1 1970, Vilcek and Ng 1971)- The model, as 
presented for interferon, is as follows (see figure l)..
The initial event - induction - is proposed to alter the 
equilibrium. Double stranded RNA is assumed to complex the repressor
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from cells that is not present on polyribosomes ( Seghal, Dobberstein 
and Tamm 1977 )• Thus it seems that a simple competition model 
will not suffice to explain interferon superinduction»
Lastly it has been suggested that a repressor system operates 
which inactivates specific mRNA ( McAuslan 1963 ). It is proposed 
that antimetabolites differentially inhibit the formation of this 
repressor ( Tan .et al 1970, Vilcek and Ng 1971)» The model, as 
presented for interferon, is as follows (see figure l)..
The initial event - induction - is proposed to alter the 
equilibrium. Double stranded RNA is assumed to complex the repressor
Figure
Figure 1 .
The r e p r e s s o r  h y o o i h e s i s .
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Figure 1.
The R e u r e s s o r  H y p o t h e s is »
Hepressor Gene. Interferon Gene.
NH2----- COOH NH2
®  / /
Inactive Repressor
( Tan 4 Berthold 1977 )
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protein in some maimer so as to inactivate it. This removes the 
repressor from the system and thus the negative control on the 
interferon gene. The gene is thus 'derepressed'. Interferon mRNA 
is then made and translated. Interferon itself is assumed to exert 
a positive control over transcription of the repressor gene. This 
system thus explains the 'shut—off' mechanism.
The use of antimetaholites 'selectively' alters this system. 
Cycloheximide is first added during or before induction. This acts 
at 2 in the diagram. Since no interferon can be made there is no 
transcription of the repressor gene. Interferon mRNA levels thus 
build up. Actinomycin D is then added which irreversibly inhibits 
RNA synthesis, so no further mRNA is made. Actinomycin D thus acts 
at 1 in the diagram. On removing the cycloheximide block by washing 
the interferon mRNA can be translated to interferon but repressor 
mRNA cannot be made so no repressor is made, in theory. However, a 
small amouQt of RNA synthesis still occurs in the presence of 
aotinomyoin 0 and therefore some repressor is made. The system 
is thus eventually 'shut-off but interferon will have been made 
quicker than normal since there was a higher concentration of inter­
feron mRNA at the onset of translation, and it will also have been 
made for longer because the repressor is made later and more slowly. 
Thus more interferon is made than in untreated cells. This model is 
based heavily on the Jaoob and Konod model and therefore must be 
regarded with certain reservations as explained earlier.
Other observations on sunerinduotion.
Only systems that are induoible with poly(rl).poly(rC) or 
UV-NDV can be superinduced. When wild type KDV is used only the early 
interferon response (i.e. interferon produoed soon after induotion) 
oaa be superinduoed. This howefer only ooours when DRB is used 
( Viloek and Kohase 1977 ) sad not when aotinomyoin is used ( DeClerq 
and Kerlgan 1970 )» In the latter oase, as with the late response 
when using DRB, the interferon yields are depressed. This has been 
generalised to the statement that only systems that show an early 
response can be superinduoed ( Vilcek, Barmaks and Havell 1972 )•
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Chick cells ( Long and Burke 1971 ) and mouse L cells ( Stewart, 
Gresser and Lockhart 1971 ) are reported not to he superinducihle, 
whereas rabbit kidney cells are ( Vilcek 1970 ); poly(rl).poly(rC) 
being used in all cases. It is suggested that the induction aonditions 
rather than the control mechanisms differ. The only evidence to 
support this view comes from work done with mouse-human hybrid cell 
lines. Some of these cells make both human and mouse interferon, 
but the proportions of the two vary greatly depending on the inducing 
conditions. This suggests that the events leading to triggering may 
be different for different inducers.. Both types of interferon 
could be superinduced, except in one hybrid where superinduction 
did not occur for either interfierom ( Frankfort et_ al 1978, Meager- 
¿t al_1979 )• Higher doses of poly(rr)»poly(rC) or the use of 
DEAE-dextram with the poly(rl).poly(rC), increases the upttake of 
the inducer ( Tovell and Colter 1967 )• It is possible that higher 
doses of inducer neutralises more repressor and thus prevents anu 
early 'shut-off*- If excess inducer is present then this will 
neutralise all the repressor and the addition of antimetabolites 
cannot make any difference to the interferon yield..
The state of repression of the interferon gene in a given type 
of cell may also determine the quantity of interferon produced. If 
the gene is poorly repressed then it will be easily induced and 
vice versa ( Tan and Berthold 1977 )•
The re-pressor.
The identity of the repressor is not known but it is assumed 
to be a protein- It has been suggested that it is an. interferon 
oligomer since this would explain the positive control of interferon 
over the repressor ( Kleinschmidt 1972 ).. However there is no direct 
evidence to support this idea.
The fact that a single metabolic inhibitor can give rise to 
small interferon yields in. the absence of an inducer suggests that 
the repressor ia very labile ( Tan and Berthold 1977 )••
The repressor is involved in regulation in two ways. Firstly 
it could have a rente in induction. Three hypotheses have been put
forward, for induction. These are the douhle-stranded RNA hypothesis 
where douhle-stranded SNA formed in or taken up into the cell is the 
inducer, which exerts positive control over the interferon genet the 
repressor depletion hypothesis ( (3) figure I ), where repressor is 
inactivated by the inducing molecule and negative control is thus 
removed) and the basal level interferon hypothesis, where low levels 
of constitutively made interferon exerts a feedback control over the 
expression of the interferon gene. The latter hypothesis is linked 
to the first two if one assumes that the repressor is interferon. 
Certain cells have been shown to produce small amounts of interferon 
in the absence of an identifiable inducer ( DeMaeyer-Guignard,
Thang and DeHaeyer 1977 ). It has thus been suggested that interferon 
has a cellular function other than its antiviral fonction. 
Interestingly, interferon oan itself bind to many inducers including 
poly(rl) and poly(rü) as well as double—stranded HNA. This is a 
curious property since the binding appears to be very specific. The 
hypothesis thus states that the role of the inducer is to bind the 
banal levels of interferon normally made by the cell and that this 
induces further intetrferon synthesis.
Secondly, the repressor inaotivates interferon mHNA. This 
could occur by two methods. The repressor could be a highly 
specific nuclease. Alternatively, the repressor oould complex with 
the mHNA in such a manner as to prevent its translation ( Vilcek 
and Hg 1971 )• The inaotivation is irreversible sinoe interferon 
mSHA activity cannot be rescued by ultraviolet irradiation of cells in 
the 'shut-off' phase. This treatment would be expeoted to inhibit 
repressor synthesis ( Vilcek, Have11 and Kohase 1976 )-
The repressor has been used to explain other observations.
These are hyporesponsiveness, ultraviolet superinduotion by 
preirradiation of the cells, and certain oonstituitive mutants.
It is unlikely that interferon itself is involved in hypo- 
reactivity for the following reasons. Hyporeaotivity oan ooour 
as soon as one hour post—induction ( Breinig, Armstrong and Ho 
1973 )• Hyporeaotivity faotora oan also be separated from anti­
viral activity and cannot be neutralised with anti-interferon serum 
( Stringfallow 1973, 1977 )• Although high doses of interferon do
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inhibit its own production ( Vilcek and Bada 1962 ) it is also 
seen that low doses enhanoe its own production ( Stewart, Grosser 
and Lookhart 1971 ). Cells oan also show hyporeactivity to doses of 
endotoxin that do not induce any detectable interferon 
( Kleinschmidt 1972 ).
Induction is a required event for hyporeactivity — low doses 
of poly(rl).poly(rC) that do not induce interferon do not give 
hyporesponsiveness to subsequent higher doses of inducer ( Billiau 
1970, Breinig, Armstrong and Ho 1975 )• Thus it has been suggested 
that the repressor is involved ( Billiau 1970, Tan et al 1970 ).
More precisely it has been suggested that the ability of the 
repressor to irreversibly inactive interferon mBNA is the cause of 
byporesponsiveness ( Kohase and Vilcek 1977 )• To account for the 
rapid onset of hyporeactivity, it is suggested that repressor 
synthesis oould be directly stimulated by the induoer, rather than 
by interferon ( Breinig, Armstrong and Ho 1975 )• Hypo- 
responsiveness is a very confused field with many contradictory 
results appearing in the literature. These results may reflect 
different amounts of repressor being synthesized in different tissues 
( Ke and Ho 1971 ).
Ultraviolet irradiation (UV) of cells before induction gives 
rise to a superinduction effect ( Linder—frimmel 1974» Noses et al 
1974 ). Where poly(rl).poly(rC) is used as inducer and anti­
metabolites used as well as ultraviolet pre-irradiation, then no 
increase over normal ' superinduotion' yields is obtained. No 
superinduction is seen with NDV induction and ultraviolet pre­
irradiation ( Msaes and Vilcek 1974 ). Thus UV superinduotion oould 
occur by an Inhibition of repressor synthesis as a result of an 
inaotivation of the repressor gene. Where a superinduotion regime 
with antimetabolites is followed production may be fully expressed 
and the repressor system fully depressed. Thus UV treatment would 
have no further effect. Indeed interferon yields fall due to the 
action of the UV irradiation on the interferon gene(s). In the 
oase of viral induction, it is suggested that superinduotion does 
not occur because of the different inducing oonditions resulting from 
a different induction site and/or triggering sequenoe ( Vileek,
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Barmaka and Havell 1972 ) , as discussed above.
Finally, selection procedures or mutagenesis have produced 
phenotypes that either continuously make small amounts of interferon:
( Jarvis and Colby 1978 ), or that make significantly higher 
amounts of interferon after induction ( Tan et al 1979 )• These 
phenotypes could be the result of a malfunctioning repressor system.
Translation of interferon mRNA.
Interferon mRNA can be translated in intact heterologous cells, 
oell-free systems and in oocytes. The oocyte system is capable of 
relatively efficient translation of exogenous mRNA's, whereas the 
other two systems yield relatively small amounts of interferon. 
Cell-free systems are apparently inefficient at translating human 
interferon mRNA's probably beoause they cannot modify the resultant 
protein ( Stewart 1979 )• Post-translational modification may he 
required for biologioal activity as is generally the case with the 
peptide hormones e.g. insulin ( Butcher, Robinson and Sutherland 
1972 ). Rouse interferon mRNA can be translated as efficiently 
in vitro as in intaot cells ( Montagnier et al 1974 )• The reason 
for this discrepancy between the two mRNA's is not known.
Translation of interferon inRNA's required spermine at oritical 
concentrations ( Montagnier et, al 1974, Pestka et, al 1977 )•-
Post-translational oontrol.
There is a lag of 20—30 minutes before intraoellular interferon 
can be deteoted in the extracellular medium ( Tan et al 1971* Mg* 
Berman and Viloek 1972 ). It is suggested that glyoosylation and 
secretion occur in this period. The synthesis of active interferon
but not the secretion of interferon can be affected by inhibitors#  . .of glyoosylation v Havell e£ ji, 1975 )» 4 smaller antiviral protein
* ~  However production of active interferon is not totally inhibited. The
effeot of such inhibitors on interferon synthesis oould result from
the Inhibition of the activity of other oellular proteins whioh do
require oarbohydrate for aotivity.
lias 136611 reported, in I» cells treated with, these inhibitors, having 
a molecular weight of 16,000 compared to native interferon which 
has molecular weights of 22,000 and 38,000. The difference in 
molecular weight is proposed to he due to differences in the 
extent of glycosylation ( Havell, Tamazaid and Vilcek 1977 )•
Chick cell extracts, that do not possess antiviral activity, 
elicit antibody to chick interferon ( German, Quero and Poindron 
1971 )» Ehrlich asoites cell extracts incubated with interferon mRNA 
for 30 minutes before addition of sparsomycin to block further 
protein synthesis, do not show detectable antiviral activity until 
incubation has proceeded for another two hours ( Pestka et al 
1977 )• These results suggest that some kind of post-translational 
modification is required to give biologically active interferon.
Intracellular interferon is trypsin resistant, unlike extra­
cellular interferon. It is suggested that intracellular interferon 
is bound inside vesioles ( Ng, Berman and Vilcek 1972, Falcoff et al 
1976, Xorser et al 1979 ) and thus is protected from the protease. 
Extracellular interferon injected into oocytes is degraded or 
inactivated. This supports the idea that interferon is compart­
mentalised after translation ( Xorser et. al 1979 )•
A rapid in vivo degradation of cytoplasmio glycoproteins has 
recently been reported ( Kalish, Chovik and Dice 1979 )• They 
support the suggestion that glycoproteins are turned over faster 
than non-glycoproteins ( Curd and Evans 1973» Olden, Pratt and Tamada 
1978, Ashwell and Xorrell 1974» 1975 ) but show that they are no 
more sensitive to pronase of chymotrypain. Thus interferon is not 
peouliar in this respeot and glycosylation may be a signal to the 
cell for selective degradation. Interferon may be degraded rapidly 
to minimise its antieellular, or other effects, in the whole animal.
The secretion of interferon is an active prooess since it can 
be stopped at 4°C even though there are large amounts of intra- 
oellular interferon ( Tan, Armstrong and Ho 1971» Field et al 1972 )«. 
The involvement of microtubules and microfilaaents are implicated 
in the production of interferon, since speoific inhibitors of their 
formation inhibits the production of interferon ( Ito, Nishiyama 
and Shimokata 1976 ). The preoise function of microtubules and
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microfilaments are not known but suffice to say that they are involved 
im many cellular and developmental processes ( Wessells et al 1971 )•
A soecifio system for the production of interferon«
Lymphoblastoid cells, and the Namalva line in particular, 
produce high titres of interferon in response to infeotion with 
negative stranded BN A viruses ( Strandsr, Mogenson and Cantell 1975» 
Volckaert-Vervliet and Billian 1978 and Zoon et al 1978 )• It is not 
known why these cells make higher titres of interferon than most other 
cells but the controlling property could lie with the transforming 
viral genetic information that most of these cell lines carry, with 
the host regulatory mechanisms or with the inducer itself. Let me 
consider these points further.
Lranhoblastoid cells.
Lymphoblastoid cells can be established from a variety of 
sources, including healthy individuals. They are lymphocyte-derived 
and grow in suspension culture for an indefinite period. These cells 
can be sub-olassed according to their origin and their possession of 
viral gene sequences. Cells derived from patients suffering from 
infeotious mononucleosis or Burkitts lymphoma generally contain 
part or all of the Epstein-Barr virus genome. The latter oells are 
referred to as lymphoma oells ( Nilsson and Ponten 1975 )• 
Lymphoblastoid oells make varying amounts of interferon either 
spontaneously ( Adams, Strander and Cantell 1975 ) 0T after induotion 
which is generally done with paramyxoviruses ( Strander, Xogenson 
and Cantell 1975 )• These oells are similarly differentially 
sensitive to the antiviral and antioellular effeots of HLeIN 
( Hilfenhaus, Damn and Johaansen 1977 )•
Epsteln-Barr virus.
Epstein-Barr virus (BBT) was discovered in lymphoma oell lines 
established from Burkitts Lymphoma ( Epstein and Barr 1964 ). It is
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a member of the Herpes group of viruses but apart from transforming 
certain cell types the virus shows very little biological aotlvity 
in vitro» The role of BBT in the formation of Burkitts lymphoma is 
not yet known but it seems that there must be certain cofaotors 
( Gunven 1975, sur Hausen 1975, Ablashi 1976, Ponten 1976, Eapp and 
Heed 1977 and Henle, Henle and Lennette 1979 )• It is, however, the 
oanse of infeotious mononucleosis and appears to be involved in 
another type of human oanoer-nasopharyngeal carcinoma.
Two types of BBT can be identified in vitro. One type is 
transforming and the other is non-transforming. The former is known 
only to be made by a single oell line, is a heterogeneous population 
of virus ( Presen et ¿1 1972 ) and lacks some of the genetic 
information of the nOn-transforming virus ( Given and Kieff 1978 )» 
Progeny virus with the properties of both viruses can be obtained 
( Traul et aj, 1977 )•■ The virus exists both in a circular form 
( Lindahl jjt al 1976 ) and in an integrated form, both having 
alkali labile bonds suggesting that HHA linkers may be involved 
( Adams r Lindahl and Klein 1973 ). The integration of the viral 
genome appears to be random ( Spira et a^ , 1977 )»■ The transforming 
strain occurs in oiroular forms that are smaller than the non- 
transforming virus ( Adams et al 1977 ) and it is possible that they 
arise by the loss of one of the two homologous reiterated terminal 
sequences present in the non-transforming viral genome. Baoh lymphoma 
oell line possesses a different number of BBT genome equivalents but 
the number in a given line remains oonstant even in oell lines that 
do not produce progeny virus ( Schwarts, Cook and H a r H s  1971 )•
It is assumed that transformation of the lymphoma cells by BBT 
is responsible for their 'immortalisation'. All oells of a given 
oell line contain BBT ( Miller 1970, Maurer et ai 1970 and Zajao 
and Kohn 1970 )» Pew oell lines produoe KBV7 and some produce only 
one BBT—related antigen — Bpstein-Barr nuclear antigen (BBNA). The 
possession of this antigen is absolutely correlated with the 
possession of BBT genetic material ( Anderson and Lindahl 1976 ).
Thus it seems likely that only a few genes are required to maintain 
transformation ( Hayward and Cieff 1976 ).O
The BBT genome is about 10 molecular weight DMA and could
in*.» t
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potentially code for about 100 proteins ( Prichett, Hayward and 
Kieff 1975 )» of whioh 33 have been identified on poly aery amide gels 
( Dolyniuk, Prichett and Kieff 1976 ). Thus it seems that in 
lymphoblastoid cells, expression of the viral genome is repressed. 
There is evidence to support this idea. Firstly, cells in a biopsy 
of Burkitts lymphoma rarely produce viral antigens, but once 
established in culture such expression often occurs, although in 
only about 1-4/6 of the oells ( Zajac and Kotm 1970 ). This expression 
can be increased by culturing the cells in the absence of arginine 
( Henle and Henle 1968 )• Secondly, latency occurs in vivo without 
any clinical symptoms, although it is not known what host factors 
govern the course of an EBV infection ¿n vivo ( Ablashi et al 1976 )» 
Thirdly, the evidence from cell-hybrids suggests that an inhibitor 
is present that prevents a productive infection. This inhibitor can 
be antagonised to allow other viral antigens to be produced ( Nyormoi 
et al 1973 )* Treatment of the cells with thymidine analogues, 
particularly bromodeoxyuridine, allows the production of viral 
antigens and a productive cycle, possibly as a result of mutation 
( Gerber et ¿1 1972 and Hampar .et ai 1973 ). The phenotypes of 
fibroblast/lymphoma oell hybrids argues againBt a virally produced 
inhibitor ( Klein et ¿ 1 1976 ). Cell surface marker expression also 
appears to be under host control ( Robinson 1977 )• The inhibition 
aots at a post—transoriptional level, since iododeoxyuridine 
treatment of Baji lymphoma oells increased the transoription of 
SBV DHA from 25$ to 50$ hut no further expression of viral antigens 
was observed. In hybrid oells such treatment gave rise to new 
antigen expression ( Tanaka e£ ai 1979 ).
In the light of the observation that certain lymphoma cell 
lines make interferon autogenously, it has been suggested that this 
interferon acts as the negative oontrol element inhibiting EBV 
expression ( Adams, Strander and Cantell 1975 )» In view of the faot 
that leucocytes that are not infeoted with EBV and other lines 
established that do not contain EBV genetic material make interferon 
in response to an inducer ( Strander and Cantell 1966 ), it seems 
unlikely that BBV plays a determining role in the expression of 
interferon. However the meohanism of production of autogenous
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interferon is unknown. This interferon is identical to virally 
induced interferon, is produced by all the cellB in a given line 
and enhances the rate of production of virally induced interferon 
( Zajac, Henle and Henle 1969 )•
TViw Hftma.1 we. line of lvnrphoma cells.
Namalva is a lymphoma cell ( Klein, Dombos and Gothoskar 1972 ) 
which grows in suspension, has no known enzyme deficiency, makes 
immunoglobin X lambda protein and has a model chromosomal number of 
45» It contains BBT M A ,  which may be a defective genome ( Prichett, 
Pederson and Kieff 1976 )« In addition to hybrid work, which shows 
that Namalwa cells contain an.,BBT repressor ( Nyormoi et al. 1973 )» 
work on BNA sequences shows that only about three BBT proteins are 
made (including EBNA). These three proteins must be sufficient to 
maintain transformation. There is regulation of transcription from 
BBV7 sequences and a selective exclusion of some transcribed sequences 
from stable polyribosomes ( Hayward and Kieff 1976 ).
Namalwa oells make both autogenous interferon ( Adams et al 1975 ) 
and virally induced interferon ( Strander, Xogenson and Cantell 1975)»
The interferon is of leukocyte type, although a small proportion 
is speoifically neutralised by anti-fibroblast interferon anti-serum 
( Havell, Tip and Tiloek 1978 )• It is suggested that these two 
antigenically different species of interferon have separate structural 
genes ( Cavalier! et al 1977 )• Namalwa cells, however, appear to 
be insensitive to leukocyte interferon in that the antiviral state 
is not aohieved (except for 73T and BBT where other host factors 
may be involved, Lidin and Adams 1975» Nowakowski et al 1973 )•
Namalwa oells are sensitive to relatively high levels of interferon 
in terms of growth inhibition ( Tolokaert—Tervliet et al 1978 ).
Beoently the optimal conditions for the production of interferon 
by Namalwa oells havo been studied ( Zoon et al 1978, Johnston et al 1979 )„
gendai virus - the virion and its replicative croie.
Sendai virus is a negative stranded BNA virus olassified as a
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paramxyovirus and otherwise known as HVJ virus or parainfluenza I.
The virion is approximately spherical consisting of an envelope 
containing lipid surrounding a helical nucleocapsid, which contains 
single stranded RNA of about 6 x 10^ molecular weight. Spikes contain­
ing the virus specific haemagglutinin and neuraminidase proteins 
protrude from the envelope. The virus replicates in the cytoplasm 
of a permissive cell with virus components being assembled at the 
cell membrane. The virus is released by budding.
The RNA represents 3.7% of the weight of the nucleocapsid, sedim­
ents of 50S in 0.1M NaCl and has a buoyant density of 1.680 in CsCl.
The virus contains a virus specific RNA dependant RNA polymerase 
( Robinson 1971 ) which produces 18 and 22S complementary RNA ( Blair 
and Robinson 1967 ). Some 50S RNA in the virions is message sense 
( Hobinson 1970 ). Passage of the virus at high multiplicity in eggs 
gives rise to the generation of incomplete genomes ( Kingsbury and 
Portner 1970 ).
Thirteen different defective genomes have been identified 
( Kolakofsky 1979 ) ranging from 4-47# of the wild type genome.
Bach strain of Sendai is predisposed to generate a specific RNA 
and shorter RNA's are not selectively amplified over the larger ones.
The mechanism of generation of these particles and the nature of the 
advantage they have over the wild type genomes are not known. Passage 
of Sendai is thus normally carried out at low multiplicity.
The haemagglutining activity of the egg passaged virus is variable 
from passage to passage whilst infectivity is retained. This is attrib­
uted to changes in the envelope such as permeability changes ( Homma 
et al 1976 ). Sendai virus passaged in tissue culture is generally non— 
infectious. The progeny virus contain a precursor glycoprotein termed 
Fo which is normally cleaved in eggs to form proteins FI and F2 by 
breakage of two disulphide bond linked chains ( Schied and Choppin. 1974 )► 
Tissue culture grown virus can be made infectious by treating with 
trypsin, which cleaves the Fo protein to VI and F2 ( Schied and Choppin 
1977 ). Hon-infactions virus retains full haemagglutining and neuramin­
idase activity but not oell fusing ability and thus FI and F2 are 
implicated in the fusion process ( Schied and Choppin 1974 ). The non— 
infeotioua particles oannot be activated by a permissive oell line and 
so the host protease responsible for oleaving Fo must be intracellular 
( Pennington 1978 ).
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Sendai virus possesses four other structural proteins plus two 
minor components.. These are the nucleoprotein (NP), L and P proteins 
found in the necleocapsid and possibly involved in the RNA dependant 
SNA polymerase activity, and the matrix (m ) protein ( Schied and 
Choppin 1977 ). The two minor components have molecular weights of 
54000 and 42000, the former being related to NP and the latter 
being cellular actin ( Lamb and Choppin 1978 ). L is a large protein 
but does not represent a precursor protein since it has a unique 
peptide map ( Emerson and Tu 1975 )•■ There are two non-struotural 
polypeptides one of which is a phosphorylated form of the M protein, 
while the other is unrelated to any of the structural proteins 
( Lamb and Choppin 1977b, 1978 ). The intracellular distribution of 
these polypeptides has been described ( Lamb and Choppin 1977a ).
The K protein may be involved in the binding of the nucleocapsid 
to the envelope during maturation ( Schimizu and Ishida 1975 )• It 
is also involved in the formation of restricted areas of plasma 
membrane which contains viral glycoproteins and thus gives rise to the 
viral envelope ( Toshida et, _al 1979 )- The haemagglutinin protein 
is a glycoprotein but is not involved in virus assembly. It appears 
to be an important factor in cell killing ( Fortner ¿t al 1975 )•
Hole of Sendai virus in interferon induction.
Sendai virus is the best inducer of interferon known giving 
high titres of interferon after infection of Namalwa cells ( Strander, 
Mogenson and Cantell 1975, and Johnston et al 1979 )• Sendai 
presumably induces as a result of its ability to form double-etrandedi 
SNA replicative intermediates.
Lymuhoblastoid interferon.
Lymphoblastoid interferon is mostly leukocyte-type interferon 
(see page 9)> Thus since most of the clinical applications of 
interferon to date have utilised HLelP ( Pollard and Kerigan 1979 )» 
lymphoblastoid oells oould provide a valuable souroe of further 
interferon to build on past data. Fibroblast interferon has not been
used a great deal because of the problems involved in handling large 
volumes of monolayer cells and the low titres of interferon generally 
obtained. The fact that lymphoblastoid cells grow in suspension 
and have an indefinite lifespan ( Nilsson and Ponten 1975 ) is an 
obvious advantage in large scale work. Fibroblast interferon also 
seems to give more severe side reactions at the site of injection 
than leukocyte interferon ( DeSomer .et al 1977 )* Other advantages 
of Namalwa cell interferon are the fact that high titres of interferon 
cam be produced in cultures without a requirement for serum ( Zoon, 
Bridgen and Smith 1979 )• This makes purification somewhat eaisier 
and production cheaper.
The main problem with lymphoblaistoid interferon is that preparat­
ions may contain not only the inducing virus but also genetic inform­
ation from the Epstein-Batrr virus residing in the cell. The former 
is sensitive to low pH and extensively inactivated. The latter is of 
particular importance since it is the only virus for which there is 
any substantial evidence for a role in human oncogenesis. As the 
genome is large and the biological roles of the polypeptides that can 
be identified in any infected cell axe not known it will be important 
to make sure that no EBV related material is present in the final 
preparations. The best way of achieving this in the long term will 
be to isolate the interferon gene ailone and sequence it in comparison 
to the protein sequence. If this can he inserted into bacterial cells, 
then no EBV expression can occur. Genetic manipulation also offers 
other advantages as previously discussed. The technique of DNA-DNA 
hybridisation using EBV complementary DNA, prepared from purified 
EBV DNA, shows no hybridisation with partially purified preparations 
of interferon from lymphoblastoid cells ( Lindahl et al 1976 ).. Thus 
one cam be reasonably sure that EBV genetio material is not present 
in these preparations of interferon.
The initial oase for the use of interferon is in cases where 
no other treatment is available (e.g. Hepatitis B), so the advantages 
of treatment with lymphoblastoid interferon must outweigh the 
disadvantatges.
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Materials and Methods.
Chemicals.
DABA (3',5 — Diaminobenzoic acid dihydrochloride) (Gold Label) was 
purchased from the Aldrich Chemical Co. Ltd., Gillingham, Dorset» 
Acrylamide; Ammonium persulphate; ferric ammonium sulphate; Folin 
and Ciocaltean reagent; n-butyric acid; sodium dodecyl sulphate; 
especially pure grade (SDS) and sodium oyruvate, were purchased 
from B. D. H. Chemicals Ltd., Poole, Dorset.
Caesium chloride (ultra pure reagent) was purchased from Bethesda 
Research Laboratories, Rockville, Maryland, U.5.A. 
5'-Chlorodeoxyuridine (CldUrd) was purchased from Calbiochem Ltd., 
London.
N, N^-Methylene bisacrylamide and N,N,N^,N^-tetramethylenediamine 
(TEMED) was purchased from Eastman Kodak Co., Rochester, Hew York,
O. 3. A.
Perchloric acid (70$) was purchased from Fisons Scientific Apparatus, 
Loughborough.
Whatman GF/C filters were purchased from Griffin and George Ltd., 
London.
2,5-Diphenyloxazole (PPO) and 1,4-di (2 (5-phenyl-oxazolyl) )-benzene 
(P0P0P), both scintillation grade, were purchased from Nuclear 
Enterprises (GB) Ltd., Edinburgh.
Soluene 350 was purohased from Packard Instrument Co. Ino.,
Illinois, U.S.A.
Ficoll was purchased from Pharmacia Fine Chemicals, Uppsala, Sweden. 
Glutaraldehyde, osmium tetroxide and uranyl acetate, were purchased 
from Polaron Equipment Ltd., Watford.
5'-Bromodeoxyuridine (5*-BrdUrd); deoxyribonucleic acid (DNA)- 
from oalf thymus; 5'-fluorodeoxyundine (FdUrd);
5'-iododeoxyundine (idUrd); 2-mercaptoethanol, type 1; 
ribonucleic acid (RNA), type from yeast and trizma base (tris 
(hydroxy-methyl) aminomethane) were purchased from Sigma Chemical 
Co. , London.
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Lead citrate and Spurrs Basin kit for electron microscopy were 
purchased from Taab Laboratories, Reading.
All other materials were the best grade available commercially.
Radiolabelled compounds.
The following were purchased 
Arnersham, Bucks.
L — "*S methionine 
86 — Rubidium 
5 -  thymidine 
5 —  3H uridine
Biological materials.
Noble agar and tryptose phosphate broth were purchased from Difco 
Laboratories, Bast Holesley, Surrey.
All media and serum were purchased from Flow Laboratories Ltd., 
Irvine, Ayrshire, Scotland.
Crystamycin (containing 600mg ( 10^ units ) of pencillin to lg of 
streptomyoin) was purchased from Glaxo Laboratories Ltd.,
Greenford, Middlesex*
Bovine serum albumin (fraction 7), oycloheximide, DBAS dextran,
N-acetyl trypsin, sodium pyruvate and trypsin type III (from bovine 
pancreas) were purchased from Sigma Chemical Co., London.
Adult chioken red blood cells were purchased from Tissue Culture 
Services.
culture medium.
All media were supplemented with 100 units/ml orystamyoin.
Bovine turbinate oella (BT). Growth medium - GMEM supplemented with 
10$ (u/v) horse serum.
Maintenance medium OMEM supplemented with 2$ (7/7) horse serum. 
Human foreskin fibroblasts (HFF). Media identical to that used for 
BT cells but horse serum replaced by foetal oalf serum.
from the Radiochemical Centre,
745 - 880 Ci/mmol.
1 mCi/ml.
42 - 47 Ci/mmol.
12 - 28 Ci/mmol.
I n r a f f r i W I 1 A fO *
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Malin-Darby Bonne Kidney cells (lIDBK). Media identical to that need 
for Namalwa cells except that foetal oalf serum was used instead of 
newborn calf serum.
Manualwa cells. Growth medium - SPMI I64O supplemented with 10$ (v/v) 
newborn oalf serum.
'Maintenance* medium. RPMI 1640 supplemented with 2$ (V/y ) newborn 
oalf serum.
Primary chicken embrovo fibroblasts prepared by the method of 
Morser, Kennedy and Burke (1973) were maintained in 199 medium +2$ 
newborn calf serum.
Buffers and solutions.
Alsevers buffer was made up as follows 1—
D—gluoose 20.5 g/l. 1
Ha Cl 4.2 " pH 6.1 - 6.2. I
trisodium citrate dihydrate 8 . j0  "  1
citric acid 0.55 " 1
Bacto agar was made up 2$ (wt/v) in distilled water and autoclaved 
at 15psi for 15 mins, immediately before use and maintained at 42°C. 
Noble agar was made up at 1.8$ (wt/v).
PEAB dextran was made up 3$ (wt/v) in PBS and stored at 4°C. 
Caoodvlate butter. 50ml 0.2M sodium oacodylate (HaiCH^JgdsOg 3Hg0) 
in distilled water plus 2.7ml of 0.2M EC1 made up to 200ml with 
distilled water.
N acetyl trypsin was made up at 2mg/ml in PBS and frozen at -20°C 
in 300ul aliquote.
Phosphate buffered saline (PBS) was 139mM HaCl containing 28mM KC1, 
7-5»M Ba^HFO^ and 0«147mM KHgPO^ (pH 7.4) sterilised by antoolaving 
at 15psi for 15 mins.
pH 2.0 buffer. 6.5ml 2M HC1 in distilled water plus 43.5“! 2M KC1 
in distilled H^O made up to 1 litre with distilled water.
TUB was 50mm tris containing 100mm NsCl and 1 M ethylene diamine 
tetra-aoetio acid (disodium salt) (pH 7*4) made up to 20 fold 
oonoentrate in distilled water and autoclaved at 15psi for 15 mins, 
before used.
W 'X
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Trypsin for monolayer cell passage was made up as follows to give 
a 50 fold concentrated stock.
Trypsin (type III from bovine pancreas)
disodium EDTA 2H,,0. 
Na Cl.
K Cl.
Olucose.
Ha. HPO (anhyd).4 4
4mg/ml.
4mg/ml.
7.j6mg/ml.
224 Ug/ml.
1.8rag/ml. 
142 jig/ml.
The solution was adjusted to pHT.O by addition of sodium hydroxide 
(IM), sterilised by filtering through a 0.2^um filter (Hillipore S.A. 
Molsheim, France) and stored at -20°C.
Trypsin for use was diluted to lx concentration with PBS to give a 
final concentration of 80pg/ml.
Scintillation mixtures.
Toluene scintillation mixture was 4g PPO per litre of toluene. 
Acidified toluene scintillant was supplemented with 1ml per litre 
of glacial acetic aoid.
Triton-toluene scintillation mixture was 1 volume of Triton X-100 
and 2 volumes of toluene scintillation mixture containing 0.266g/l 
final concentration of POPOP.
Electron microscopy - Spurrs resin.
The resin from the Taab Spurrs resin kit was made up immediately 
before use as followsi-
Epoxy resin ERL 4206 (vinyl oyolohexene dioxide)
Hardener NSA (nonenylsucoinio anhydride)
Plexibiliser HER 736 (diglyoidyl ether of poly­
propylene glycol)
Accelerator 5—L (dimethyl aminoethanol)
10.Og. 
26.Og.
The first three ingredients are swirled to mix before the 5 -1 is 
added. After shaking to disperse the accelerator the resin is 
ready to use.
Methods«
Growth of viruses»
Semliki Forest virus (SFV) stock was a plaque purified virus 
originally obtained from Dr. J. Porterfield, National Institute of 
Medical Research, Mill Hill, London*
Primary stocks were passaged in the brains of suckling mice 
( Walters, Burke and Skehel 1967 )•
Secondary stocks, which were used for erperimentation, were prepared 
from suspension cultures of chick embroy cells using the modification 
of the method of Zwartow and Algar (1968) as described by Kennedy 
and Burke (1972)«
Clarified supernatants supplemented, with 5$ (v/v) newborn calf serum
from the latter procedure were stored at -70°C until use.
Sendai virus (H7J) was a gift from Dr. N. B. Pinter, Wellcome Research
Laboratories, Beckenham, Kent. The virus was maintained by passage2+ 2+of dilute virus supplemented with ImM Ca and ImM Mg ions, in the 
allantoic cavity of 10 day old embroyonated eggs in the manner of 
Kingsbury and Portner (1970). f
Allantoic fluid was collected 60 hours after innoculation from 
chilled eggs and clarified by centrifugation (2,000g for 10 mins.).
The supernatant was frozen in aliquote in an ethanolt dry ice bath 
and stored at 70°C.
Subculture of cells.
Suspension cells. Namalwa cells obtained from Wellcome Laboratories, 
Beokenham, Kent, were routinely passaged every 2-4 days by dilution 
of the culture with growth medium until the cell density was about 
0.5 x 10** cells/ml. Occasionally cultures were additionally buffered 
with 2M NaCH. Incubation was at 37°C.
Monolayer cells. Bovine turbinate (BT) cells were a gift from Dr. A.
W. MoClurkin, National Animal Disease Centre, Ames, Iowa, U.3.A.
HFF cells were derived from human foreskin fibroblasts and were a 
gift from Dr. T. Merigaa, Stanford University.
Mai in-Darby bovine kidney oells (KDBK) were a gift from Dr. Appleyard, 
Wellcome Researoh Laboratories, Beokenham, Kent.
V f '
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BT, HFF sad MDBK cells were passaged in their respective growth 
media using the following protocol. Honolayers of cells were 
washed 3x with 50ml PBS to remove serum. 5-10ml trypsin solution 
was added and the cells incubated at 37°C. Cell clumps were broken up 
by pipetting and dispersed to flasks for appropriate dilution 
(dependant on growth rate) in growth kedium. Except for flasks 
containing MDBK cells, the flasks were gassed to 5$ (v/v) with C0^ 
and incubated at 37°C* Chicken embroyo fibroblasts were used as 
primary cultures prepared from 1 1 day old embryonateid eggs and not 
suboultured. These cells were seeded in 199 medium plus 5$ newborn 
calf serum at 10^ cells/5cm petri dish and incubated for 24 hours at 
37°C* Thereafter oells were maintained in maintainence medium until 
used. CEP cells were incubated at 37°C in an 95$ air/5$C02 
atmosphere.
Determination of cell number was done using aa improved Neubauer 
counting chamber with cells suitably diluted with PBS and mixed ltl 
with PBS containing 0.1$ trypan blue. Only cells excluding the dye 
were considered viable and counted.
Induction of interferon.. Unless otherwise stated the induction of 
interferon in Hamalwa oells with Sendai virus was as followsi- 
Namalwa oells were oentrifuged from growth medium (2 ,000g for 5 mins.) 
and resuspended in maintainence medium at 1.0 x 10^ cells/ml. 100 HA 
of Sendai virus per ml ( i.e. per 10^ oells ) was added and the oells 
incubated for 24 hours at 37°C. The oells were pelleted from the 
medium by oentrifugation (2 ,000g for 5 mins.) and the supernatant 
dialysed against pH2 buffer at 4°C for 24 hours or longer. Where 
necessary the dialysate was returned to neutral pH by dialysing 
against oold PBS for eight hours or more.
Ixfluotfton ,wjth deoxyoytidinet.
Deoxyoytidine HC1 in PBS adjusted to pH7 with NaCH was used in the 
pretreatment medium in the presence or absenoe of 5'-BrdUrd where 
indicated.
Induction with butyric acid.
The conditions given here were those used by Dr. H. Johnston of 
Velloome Researoh, Beokenham (personal oommunioation)*
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Induction with thymidine and its analogues«
^»-BrdUrd. CldUrd. FdUrd and IdUrd.
The same induction as normal with conditions altered where specified. 
Pretreatment was with 25/ig/ml of 5,_BrdUrd in PBS (or equivalent (8l.4mM) 
of other analogues or thymidine itself) in the normal medium for 48 
hours, unless otherwise specified.
Note that unless specifically stated none of these chemicals 
were present during the induction and production of interferon, 
since the cells were removed prior to induction by centrifugation 
and replaced in maintenance medium which was not supplemented 
with these chemicals.
Assay for interferon. The method used was the RNA reduction assay 
by Atherton and Burke (1975)* Monolayer cells are grown in 
scintillation vial inserts (2 x £  inch), being seeded at 1 x l o V  
vial in growth medium and incubated.: at 37°c in 95% air/5$ CO^ 
until confluent. The medium is removed and dilutions of interferon in 
maintenance medium added to separate vials in a volume of 
0.5ml/vial. A standard preparation of interferon calibrated against 
the 69/l9 human leukocyte interferon standard (N1H, containing 5 »000 
reference research units/ml) was always included for every tray of 
200 vials. Vials without interferon are also inoluded. After overnight 
incubation the interferon is removed and the monolayer cells 
challenged with Semliki Forest virus at a 1 in 20 dilution from 
stock in maintenance medium supplemented with lpg/ml actinomycin D 
and using 0.2ml/vial (about 50 to 100 pfu/cell). Controls for non 
interferon treated infected cells and uninfected cells are included.
After 2.5 hours incubation at 37°C, uridine (lpCi/vial) was 
added in 0.2ml maintenance medium for a further 2.5 hours.
Incorporation into virus specific RNA will occur in the presenoe 
of aotinomyoin D. Incorporation is terminated by removal of the 
medium and addition of oold 5?6 TCA. The monolayers are washed with 
oold 5% TCA and oold ethanol and dried at 60°C. 0.2ml 'Soluene'
(diluted 1>30 in toluene) is added to dissolve the monolayer and 
subsequently 3ml of aoidified toluene sointillant added. Vials were 
counted for radioaotivity in a Packard 3385 at 10% gain. The titre 
of interferon is determinsd as the log1Q dilution at whioh
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incorporation of uridine into virus specific RNA is reduced by 
5056 compared to non interferon treated cells. The standard interferon 
is inoluded such that the titre obtained can he corrected to 
reference research units (denoted U/ml). Titres are quoted herein 
as U/ml/lO^ cells unless otherwise stated.
HA test for Sendai. The haemagglutinating properties of Sendai can 
he used as a quantitative assay for Sendai virus particles, though 
the assay detects all virions he they infectious or not. The virus is 
diluted one hundredfold and then every twofold using PBS as diluent. 
The virus is titred in 250pl, adding 25pl of 556 adult chicken red 
hlood cells in alsevers solution. The last dilution at which the 
erythrooytes agglutinate is called the titre and converted to the 
titre/ml referred to as HA/ml.
Plaque assay« General method.
5cm Petri dishes containing monolayer cells were washed three times 
with BBS to remove serum and incubated with a dilution of virus. After 
a period of time the innoculum was removed and 4-5ml of maintainence 
medium containing a final concentration of 0.9/6 (wt/vol) Noble agar 
and 100 units/ml orystamyoin placed over the cells and allowed to 
set. Plates were then incubated at 37°C in 95% air/5% CO^ until 
stained with 0.025/6 neutral red in buffered Earles saline for 1 hour. 
Plaques were oounted by eye.
For Spy. The monolayer oells were primary CEP's. The innoculum 
contained 0.0755^ (y/v) DEAE dextran to increase the plaquing 
efficiency and was 0-5ml. Incubation with the innoculum was 2 hours 
at 37°C. Incubation with overlay was 1-2 days.
For Sendai. The monolayer oells were KOBE cells. The medium used 
for dilution of the virus was BFKI I64O without serum but containing 
10$ tryptose phosphate broth. The innooulum was O.lml/plate.
Inoubation was 1 hour at room temperature. The overlay medium was 
supplemented with O.I56 (wt/vol) DBAS dextran and 2pg/ml of N-aeetyl 
trypsin (final concentrations) and 156 (wt/vol) bovine serum albumin. 
Quantitation of SPV specific RNA. Hamalwa oells were resuspended 
at 2.5 x 10^/ml in EPMI 1640 + 2% NCS at 37°C, following oentri- 
fugation (2000g for 5 mins) from growth medium. At sero time 
aotinomyoin D (lpg/ml) was added to the oells. After 1 hour 3F7 was
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added to half the culture at approximately 20pfu/cell. Samples from 
both cultures were then labelled for periods of 1 hour with 2QjuCi 
of uridipe, incubated at 37°C. Incorporation of uridine was 
stopped by the addition of one volume ice cold PBS and centri­
fugation (2 ,000g, 5 mins).
Quantitation of radiolabel - general method.
TCA précipitable incorporation of radiolabel was determined by 
collection of the precipitate on Whatman GP/c filters by filtration. 
The folters are washed with 2 x 10ml ioe cold 5$ TCA, 2ml ice cold 
ethanol and 2ml ice cold acetone. The filters are dried under an 
infra red lamp and counted in a Packard Tri Carb 3385 in toluene 
scintillant. Gains used were 70$ for tritium and 13% for sulphur—35» 
TCA soluble radioactivity was determined by counting a 25Qpl sample 
in 3ml of triton—toluene.
Incorporation of radioactive precursors into Namalwa cells.
Namalwa cells were resuspended in serum free RPMI 1640 prior to 
infection with Sendai virus. Subsequently the cells were labelled 
for 1 hour at 37°C with either ^uCi/ml of uridine or 2pCi/ml of
thymidine. TCA precipitates were prepared as above. The TCA soluble 
supernatant was also sampled for radioactivity by placing 25Qpl into 
3ml of triton-toluene scintillant and oounting in the normal manner.
Por 35S methionine labelling the procedure was similar (2jiCi/ml) 
except that cell samples were starved for methionine by incubating 
them in GMEM-methlonine at 37°C for 30 mins, prior to the addition of 
label. TCA soluble and preoiptable counts were collected as above.
Labelling with Bubidlum-86.
86The influx of Rb was determined by the addition of about 5QpCi 
86 6 Rb CIgCaq) to 100ml of Namalwa cells at 2 x 10 /ml in RPMI 1640
medium without serum and incubated at 37°0. Efflux was determined 
by prelabelling Namalwa cells for 1.5 hours and determining radio­
activity in the same maimer as for influx.
Incorporation or loss of label was stopped by the addition of 
2 volumes of ioe cold PBS at 4°C at 2,000g for 10 mins. The cell 
pellet was taken up in 1ml oold TCA and oounted for radioactivity 
in a Packard Tri Carb 3385 at 1.5$ gain using triton-toluene 
sointillant.
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Two dimensional gel electrophoresis.
Sample preparation.
Samples from Namalwa cells incubated with 250pCi ■'S methionine 
in GMEM without methione, were prepared as follows*- 
Incorporation was halted by addition of ice cold PBS and the cells 
centrifuged out of the medium at 200°g for 5 mins. The pellet is 
washed with cold PBS and recentrifuged. Cold 5$ TCA is added to the 
pellet and the precipitate collected by centrifugation at 5 ,000g for 
10 mins. The precipitate is taken up in buffer B (O.OIX Tris HC1 pH7-4, 
5mM MgClg and 50pg/ml pancreatic HNase). A final concentration of 
50pg/ml DNase is added and incubated on ioe for at least five minutes. 
Urea is added to a final concentration of 9*. One volume of buffer A 
(9.5* urea, 2% (w/v) NP40, and 2% ampholines made up of 1.6# pH range 
5-7 and. 0.4# range pH 3—10, and 5$/^-meroaptoethanol) is added and 
samples either run immediately on an isoelectric focussing gel or 
frozen at -20°C. Two dimensional electrophoresis was carried out by 
the method of O'Farrell (1975) using isoelectric focussing as the first 
dimension (pH 3.5-IO) and 8-20# gradient polyacrylamide gel electro­
phoresis in the second dimension.
Chemical determination.
DNA was measured by the method of Setaro and Morley (1977). Namalwa 
cell DNA was prepared by preoipitating whole cells with 20# TCA and 
then sonioated on ioe. The precipitate was collected by oentri- 
fugatlon (5,000g, 10 mins.). The pellet was washed by 5% TCA and 
re-oentrifuged. DNA was extracted by heating the pellet at 70°C in 
0-5* perchloric acid (PCA) (in distilled water) for 15 mins. The 
precipitate was repelleted and freBh 0.5* PCA added and the 
extraction repeated. Both supernatants were combined and assayed 
with diaminobenzoio acid oolourimetrioally at 420mm in a Gilford 
250 speotrophometer. Protein was determined by the method of Lowry 
(l95l) using a sample of the initial TCA precipitate from above.
Cloning of Namalwa cells from single pells.
The baaio method is the agar pearl technique ( Hinamura and Grace 
1968 ). Namalwa cells were grown at densities between 1 and 2 x 10^/ral 
for two weeks, never reaching densities greater than 5 * lO^ml to 
seleot for better growth prior to oloning. Noble agar (Difoo) 2$ 
or agarose (Sigma), 2.0# in distilled water, were used freshly 
ant00laved and at a final oonoentration of 0.4$ for plating in
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miorotitre plates or 5cm petrl dishes (Flow). Glasgow modified 
minimal essential medium (CXEH) (Flow) was used at lOx 
concentration for the following mixture*
lml 2.056 agar at 42°C was added to a warm bijou containing*—
IO71I sterile sodium pyruvate (500mM in distilled water).
IOO71I 10 x  GMM.
80^ x1 556 HsHC03 (in distilled water).
200»1 foetal bovine serum (Flow).
3^6mls of cells in GMBH + 2056 foetal bovine serum at an 
appropriate dilution.
Plates were overlayed with 2—5ml CBtHC + 2056 FBS and miorotitre 
plates with 50pl of the same and incubated at 37°C, 5% CO^ for 
about 2 weeks before colonies appeared.
Preoonditioned medium was made from a 2*3 dilution of normal 
medium and the supernatant from cells grown for 48 hours in normal 
medium from a density of 4 x 10^ oells/ml, and then filtered 
through a 0.22p  millipore filter. This was used to replace the 
standard medium as diluant and overlay for the cells in some 
experiments.
Colonies were pioked with pasteur pipettes from the agar when 
visible under a Wild Heerdrugg Ltd. binocular miorosoope and 
transferred to miorotitre plates with 200|al of RFHII64O plus 2Gj6 
FBS medium containing lmB pyrivate and fresh glutamate and the agar 
dispersed by pipetting up and down in the well. Clones of eella 
that grew well after dispersal were transferred to bijoux with 1ml 
fresh medium and diluted further as determined by trypan blue 
determination of oell density.
Ultraoentrifugation.
The buoyant density of cellular OKI was determined by oentrifugation 
at 44,000 rpm in a Beokoan model E ultra oentrifoge run overnight 
to equilibrium. The density gradient used was caesium ohloride 
( f  « 1.400 g/ ea ) and a marker VBA. from B.eoli ( 1.710 g/sm^)
was used for oalibration of the gradient. The density of the DHA'. 
was determined using the formula p »  p m u»2 Ct 4 " f m O  aio"'®
g/om? where r ■ 5 .7  + a/dj a  - distance of band from the oentre of 
rotation, d - magnification factor and w - 2.123 x 10‘ (Sohildkrant
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et al 1962 ).
Determination of mole fraction of 5*-BgdUrd in cellular DNA.
This was calculated, using the formulae of Round (1967) and Hackett 
and Hanawalt (l966).
Detenainatinn of the DNA content of cell nuclei by micro­
densitometry.
Feulgens reagent was made up as follows* l.Og basic fushin plus 
200ml hot distilled water was filtered. After addition of 20ml 1M HC1 
and 2.0g potassium metabisulphate the solution was left in the 
dark until colourless. Discolourisation was ensured by addition of
l.Og activated charcoal mixed for 2 hours and filtered. The resultant 
reagent was kept in the lark at 0°C. Sulphite water used to remove 
non specific staining was freshly made as follows* 10ml of 5$ (wt/vol) 
potassium metabisulphite in distilled water and 10ml of 11<I HC1 was 
made up to 200ml with distilled water.
Staining was performed on cells dried onto a microscope slide 
as follows* The cells were fixed for 15 mins, using ethanol/acetic 
acid (3*1 v/v) and then washed twice with 95$ ethanol, covering the 
cells for 5 mins, each wash. A small amount of water was added to 
the slide and 5M HC1 added to hydrolyse the sample (20 mins.). The 
UC1 was rinsed away with three changes of distilled water ( 3 x 5  mins.). 
The slide was placed in Peulgens stain for 90 mins, in the dark. The 
stain was rinsed away with three changes of sulphite water and one of 
distilled water (4 x 5 mins.). Finally the sample was dried using 70$ 
ethanol (5 mins.), 95# ethanol (5 mins.) and drying in air. The sample 
was visualised under oil immersion with a microdensitometer ( Vickers 
K85 integrating miorodensitometer at a wavelength of 560nm ). A 
standard maak was used which just enclosed the largest cell nuclei and 
the stain quantitated for each nuclei ( at least one hundred per sample). 
Quantitation is determined by absorbance of the sample. The figures 
presented are in arbitrary units since the instrument was not set up 
for absolute quantitation.
Preparation of samples for eleotron microscopy. *7
The basic method is that of Spurr (1969)* using soft resin. 5 x 101 
cells per sample were pelleted (2,000g, 5 mins.) and washed twice 
with ioe oold PBS. The oells were fixed for a minimum of 1 hour in 
2$ glutaraldehyde in PBS on ioe. Exoess fixer was washed away with
.r; ♦  * »-v - k ,
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cold. PBS twice and the final cell pellet taken up in 1 ml PBS and 
spun in a microfuge. The PBS was decanted and 1.0ml of 1.0$ osmium 
tetroxide in PBS added and the cells resuspended. After 1 hour on 
ice the osmium tetroxide was replaced By 1 ml 1.3$ uranyl acetate 
in distilled water and the sample left for 30 minutes at room 
temperature. The stain was removed By centrifugation and the sample 
carefully dried By treatment with increasing concentrations of 
ethanol in water on ice for 10 «Unites each. 20, 40, 60 and 100$ 
ethandl treatments were used. The final ethanol was removed after 
centrifugation and 250 i^l of 100$ ethanol added. 0.5ml of resin was 
added and the sample thoroughly resuspended. After 30 minutes at room 
temperature the tuBe was topped up with resin and the sample mixed 
and left for 30 minutes. After centrifugation the sample was re­
suspended in neat resin for a further 30 minutes and then this step 
repeated and the sample left overnight. The sample was then centri­
fuged and resuspended with 2-3 drops of resin and transferred to 
embedding capsules, previously air dried at 30-60°C. The capsule 
was carefully topped up so as not to disturb the pellet (to about 
2mm from the top). The resin was the polymerised at 80 C in a 
preheated oven for at least 24 hours and air cured at room temp­
erature for a further 24 hours.
Thin sections.
Thin sections were cut with a Leitz diamond knife on a Reichert 
"0m U2" ultramicrotome and transferred tto copper grids and dried in 
air. Further staining was then done with 2$ uranyl acetate in 
distilled water and 0.5$ lead citrate in 0.1M NaOH in COg-free 
distilled water as followst 3 minutes in uranyl acetate, rinse in 
distilled water, then in Q.01M NaOH, 1 minute in lead citrate, 
followed By a rinse in 0.01M NaOH and 5 minutes in distilled water. 
Grids were dried in air Before use. A transmission AEI Corinth 275 
electron microscope was used to visualise the sections using an 
accelerating voltage of 60KV. Electron micrographs were taken on 
70mm Ilford Line Film N4E5O.
Scanning electron microscone.
Samples were prepared as follows Below, this Being the most suitable 
method for reducing cell surface serum contamination. Cells were
h i :
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grown for two days in maintenance medium and transferred to RFMI 
without serum after washing three times with PBE. After two hours 
the cells were centrifuges (2,000g for 5 mins.) and resuspended in 
PBS. Cells were filtered onto Whatman GF/C filters under gravity and 
cells were fixed in 2.5# glutaraldehyde in cacodylate buffer and 
critically point dried. Visualisation was in a Phillips $00 
scanning electron microscope.
For references to preservation of samples see Anderson (l97l) 
and for critical point drying see Cohen (1974).
Cell size.
Changes in cellular size were recorded using a Model ZBI Coulter 
counter with a Coulter Channelyser C1000 and XX recorder II.
Absolute size was determined using a 12„92u diameter latex bead 
standard. Samples were diluted 1*4 in "Isopon" ( Coulter Electronics 
Ltd., Harpenden, Herts.) and recorded at an amplification of 32 or 
64, current of 1 mA with a 70 um pore. Cell volume was calculated 
from the following formula*
Cell voltqne (u^) ■ ( Channel number + ) x base channel
threshold x Tf.
Tf. is determined using the latex bead standard assuming a perfect 
spherical shape.
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RESULTS
I. Optimisation of the system for interferon prodaction.
The optimisation, of the system requires the variation of two 
parameters - the amount of inducer and the cell density. The 
interferon yields from cells induced at differing densities 
with ISO HAD/ml of Sendai virus are shown in figure 2. The insert 
shows the actual interferon yields obtained, while the figure 
itself shows the interferon yield calculated per million cells and 
plotted arithmetically (instead of logarithmically) to emphasise 
the narrowness of the optimal region. As can be seen 1 x 106 cells/ml 
is the optimum and is used hereafter unless otherwise specified.
The effect of varying the amount of inducer is shown in Table 1. The 
optimum amount is about 100 HAD/ml, which was adopted as a standard 
condition. It can also be seen that very little interferon remains 
inside the cell after induction and that this does not vary signifi­
cantly with differing amounts of inducer.
Interferon titres were routinely tested after 24 hours induction. 
When interferon is titred at earlier times (fig. 8) it oan be seen 
that interferon release is completed by 12 hours.
It is not known why Sendai virus is the best reported inducer 
and because the identity of the inducing molecule itself is not 
precisely known, finding the answer to this question would be difficult. 
However a starting point for that kind of study is to investigate 
the effect of the virus on the producing cell.
The haemagglutination assay for Sendai virus did not reveal any 
significant quantity of virus even using large infecting doses or 
high cell densities (Table 2). Also, since the cells were frosen 
and thawed before assay, there is no large quantity of intraoellular 
virus particles. These titres of virus probably represent virus that 
had attaohed to the oells and had not been removed by washing. This 
contrasts with the replication of Semliki Forest virus in Namalwa 
oells. Infectious* virus as deteoted by plaque assay is released in 
large quantities (Tahle 3). Viral directed EVA, as deteoted by the
incorporation of radioactive uridine into Namalwa oells in the 
presenoe of aotinomyoin D (conditions under whioh the viral RNA 
dependant HNA polymerase is active but oellular RNA polymerases
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3Table 1. The ootimisation of interferon yields
fromi Namalwa cells with resoect to
the inducer - Sendai virus.
Sendai virus Interferon Yield
( HAU/lO6 cells ) (i°e10 u/ml/io<^ cells '
Intracellular* Extrace!
0.32 C  1 <1 1
0.64 c  1 C l
1.28 nd 2..2
1-60 < i 2.3
3 »20 hd 2.T
6.40 2.2 2-4
12.8 2.0 2.4
19.2 2.,2 3.6
51.2 2.1 3.7
96.0 2.4 4.6i
192.0 2-5 4.4
ND = Not done.
* Intracellular interferon titred by washing cells with 
cold PBS (2x), (after removal of extracellular medium 
by centrifugation), and sonicating the pellet in 2ml 
of maintainence medium» Titres are uncorrected»
JufliCirff. de-WniinoflonS.
Table 2, Infection of flamalwa cells ith 
Sendai virus.
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Sendai virus 
iLi/lO° cells 
3.2 
6.4 
12.3 
32 
96 
320 
°60
Virus litre ( EA/^l )
( 24 hour-’ po t  infection ) 
< 8  
<8 
<8 
8 
8 
16 
32 *
Cell density*
(cells/ml) Virus titre 
( 2/ hour; post
0.4 < 8
0.6 < 8
0.8 < 8
1.0 < 8
2.0 8
4.0 e
6.0 8
8.0 16
10.0 16
* Namalwa colls infected with 100 HA/'ml Sendai virus.
DupliCitft. dd(rmm<xbons.
Table 3. Cumulative yields of SF7 released, from 
infected. Hamalwa cells.
Time post-infection (hour»)
2
3
4
5
6
7
8
Infectious virus (pfu/ml)
1.5 x 103
1.5 x 103
1.6 x 103
3.6 x 103
1 x 104
2 x 104 
2.3 x 104
Yields from Namalwa cells infected with ca. 50 pfu/ml
Q
SFV (from stoolc 1.2 x 10° pfu/ml), the cell density being 
1 x 106/«1*
T*)o duplicate dtTBrmmixt'ons ■
*•-
. r jt .,
$  «...
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are largely inhibited), is also accumulated in large quantities (fig.3). 
This shows that in spite of the report that Namalwa cells produce 
small quantities of autogenous interferon ( Adams et. al 1975» Tovey 
et al 1977 )» the Namalwa cells axe not in a self-induced 'anti­
viral* state, since infectious SFV is produced. Thus Sendai virus 
replication is unlikely to be inhibited by this interferon. Sendai 
virus replication in Namalwa cells thus appears to be abortive and 
the block must occur before maturation of the virus. If double- 
stranded SNA is the inducer, then the virus must at least be able to 
infect the cells and replicate its RNA.
The effect of Sendai virus on cellular macromoleculax synthesis 
was investigated by studying the incorporation of radiolabelled 
precursors of protein, RNA and DNA synthesis and by resolution of 
individual proteins on two dimensional polyacrylamide gels.
There appears to be a slight but reproducible réduction in 
the incorporation of radiolabelled precursors into TCA précipitable 
material (fig. 4 and Table 4) but no large change is seen, as may 
occur if the Sendai virus is replicating to a significant extent. The 
incorporations are presented as the ratio of incorporation between 
infected and uninfected cells since the actual incorporation varies 
between experiments, while this ratio remains similar. The depression 
is at the limit of determination of the method but consistent. Table 4 
clearly shows that thymidine incorporation is reduced by around 3056 
while uridine and methionine incorporation are depressed by 1055 or so. 
The pool sizes of the radiolabels as measured qualitatively by TCA 
soluble uptake into Namalwa cells shows a similar fluctuation for 
uridine and methionine to the TCA précipitable determinations. The 
thymidine pool sizes determined this way show that the ratio between 
infected and uninfected cells is about unity. Thus the depression 
observed for thymidine incorporation into DNA is independant of 
changes in the thymidine pool. Whether the depressions in the pool 
size of the two other precursors represents the cause or effect of 
the depression observed for protein and RNA synthesis was not determined.
Analysis of the proteins synthesized in uninfected and infeoted 
Namalwa cells was determined by two dimensional electrophoresis 
(fig. 6). The proteins produced are essentially similar, with a few
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The effect of Sendai on macromolecular synthesis in 
Namalwa cells.
0»
Incorp ration of labelled uridine (a - A ) , methionine 
(o - d ) and thymidine ( 0-C ) into Namalwa cells, 
a) uninfecteu Namalwa cells -TCA preciritab e incorporate .. 
h) uninfected Namalwa cells -TCA soluble incorporation.
c) Sendai infecteu Namalwa cells -TCA précipitable 
incorporation.
d) Senuai infected Namalwa cells - TCA sol ble incorporation.
* Incorporation is determinea as the percentage of the coun.s 
per minute recorded comnareu to the incorporation (of the
given isotope) determined as the first point and defined 
as 100%.
CD -
U3 -
Tim
e
 
Post*!nfection 
t hours]

Table 4a,
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Incorporation of uridine, methionine and 
thymidine into TCA precipitates of 
Namalwa cells.
Uridine Time
2-3
post-
3-4
-infection (hours) 
4-5 5-6 6-7 7-8 8-9 9-10
Infected cells 100 120 110 116 85 86 106 103
Uninfected cells 100 111 116 97 81 91 103 100
Methionine
2-3 3-4 4-5 5-6 6-7 7-8 8-9 9-10
Infected cells 100 93 112 114 123 141 124 117
Uninfected cells 100 96 114 107 119 111 107 127
Thymidine
2-3 3-4 4-5 5-6 6-7 7-8 8-9 9-10
Infected cells 100 119 113 98 116 100 94 88
Uninfected cells 100 120 112 110 118 104 97 78
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Table 4b» Incorporation of labelled uridine, methionine 
and thymidine into Namalwa cells - TCA 
soluble determinations.
U r i d i n e  Time p o s t - i n f e c t i o n  ( h o u r s )
2-3 3-4 4-5 5-6 6-7 7-8 8-9 9-10
Infected cells 100 136 115 99 126 134 132 129
Uninfected cells 100 106 113 77 119 117 117 116
Methionine
2-3 3-4 4-5 5-6 6-7 7-8 8-9 9-10
Infected cells 100 87 97 87 75 80 81 95
Uninfected cells 100 94 98 117 101 77 87 124
Thymidine
2-3 3-4 4-5 5-6 6-7 7-8 8-9 9-10
Infected cells 100 79 100 85 82 90 118 97
Uninfected cells 100 87 86 92 78 81 123 126
Figure 5
Ratio of the incorporation of labelled uridine, 
methionine and thymidine into infected and uninfected 
iJamalwa cells.
Incorporation of labelled uridine (A.-A), methionine 
(q — q ) and thymidine (C-0) into ilamalwa cells.
a) rPCA précipitable incorporation.
b) TCA soluble incorporation.
* Incorporation is determined as the ratio between the 
count per minute recorded for Sendai infected Kamalwa 
cells and uninfected cells.
fîmes of 3 experiments duplicate deteminaiion-».

Two d i m e n s i o n a l  g e l  e l e c t r o p h o r e s i s  o f  i n f e c t e d  and 
u n i n f e c t e d  c e l l s .
a )  Na. .a lw a  c e l l s  i n f e c t e  w i t h  U en dai v i r u s  and  l a b e l l e d
35w it h  S - m e t h i o n i n e .
b )  U n i n f e c t e d  c e l l s .
T h e s e  g e l s  w ere  p r e p a r e d  b y  th e  m ethod o f  O 'F a r r e l  ( s e e  M ethods 
f o r  d e t a i l s ) .
Figure 6.
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H-17
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Figure 6
Two dimensional gel electrophoresis of infected and 
uninfected cells.
a) Na.nalwa cells infected with oendai virus and labelled
35with vS-methionine.
b) Uninfected cells.
These gels were prepared by the method of O'Farrel ( see Methods 
for details).
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see Methods
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additional proteins produced in infected cells (arrows). Certain of 
these additional proteins have the sane molecular weight but several 
isoelectrio-focussing points (pi's). This may be due to the presence 
of varying amounts of carbohydrate on identical protein. Only a few 
gels were run so it is possible that these additional spots are not 
reproducible. Certainly no major new spots can be seen in infected 
cells suggesting that Sendai specified proteins are not made to any 
significant extent in Hamalwa cells.
Thus it seems that Sendai virus has very little effect on 
Naaalwa cells and does not exhibit host cell cut off. The proteins 
that are possibly viral specified are not present in high 
concentrations as judged from their density relative to other 
cellular proteins. This supports the idea that Sendai infection 
of Namalwa cells is an abortive infection. One reason why Sendai 
virus is a good inducer may result from the fact that interferon 
production is not interfered with by any anticellular effect of 
the viral replioative cyole over the period of interferon production 
i.e. 12 hours.
II. Cloning of Namalwa cells
Namalwa cells make very variable yields of interferon in 
response to Sendai virus. The variation can be due to the presence 
of too low a quantity of inducer (presumably not all the cells are 
infected) or due to the effects of cell density as first reported by 
Strander, Mogenson and Cantell (1975). The reason for the latter 
effect is not known. However under standard conditions variation 
still occurs. This variation has implications in determining the 
significance of any given result and may also be important if it 
reflects the quantity of mRNA for interferon present in the cells 
for both the oocyte assay (see above) and purification of IPtaRNA 
and for the preparation of a radioimmuno—assay to replace the 
biological assay for interferon activity.
A  possible explanation for the variation is that not all the 
cells in a culture make interferon or that sub-populations of cells 
exist that make different amounts of interferon. There are two ways 
to investigate this problem. One is to measure the interferon yields 
of individual cells ( Rodgers and Merrigan 1974) which limits the 
number of cells one can look at, or use the single cell assay 
technique of Kronenburg (1976). Alternatively the cells oan be 
cloned from individual cells. Since Namalwa are Burkitt lymphoma 
cells they have a high plating efficiency in agar ( Nilsson and 
Ponten 1975 ). Thus the agar-pearl technique of Hinamura and Grace 
(1968) can be used. Other investigators have sucessfully used this 
method with other lymphoblastoid cell lines, though chiefly to 
determine Epstein-Barr virus genome contents per cell ( Zajac 
and Cohn 1970, Maarer, Inamur and Wilbert 1970, Zajac, Henle and 
Henle 1969 ).
Other methods are available for oells that will not grow in 
agar such as the use of feeder layers and liquid oulture ( Presen 
et >1 1977, and Eiller, Stitt and Hiller 1970, Povey at a^ 1973 )•
Individual oolonies can be picked and grown up to cultures 
large enough to be induced for interferon. There are problems with 
this technique as the karyotype of the olones does not appear
to be stable and. a heterogeneous population, occurs relatively 
rapidly. Several determinations are thus required to determine 
stability and variation.
Results.
Clones of Namalwa cells were obtained over a period of three 
months, their establishment being slow and difficult. Ten clones 
were selected and tested for their interferon production (Table 5)« 
Subsequently the clones could not be maintained and recovery of 
the cells from liquid nitrogen was very poor which inhibited their 
reestablishment. The reason for this behaviour is not understood.
Clumping of the cells varied between lines (compare fig.7a with 
fig.7b) although this is dependant to some extent on cell density 
(compare fig.7b with fig. 7c).. The growth rates (fig.8) were 
significantly different but interferon production showed variation 
between clones that was only at the limit of error in the assay 
determinations (Table 5)* Variation between passages is also as high.
It seems unlikely that the variation that may be present between olones 
could aooount for the variations seen in the normal parental oulture.
It is possible that the selection favours fast growers and that such 
cells all produce interferon.
A. subsequent oloning using 10 x RPKI 1640 medium in place of 
10 x GMEK medium led to the rapid establishment of clones which 
could be maintained for long periods with good - Viabilty and 
although recovery from liquid nitrogen was poor, lines oould be 
reestablished. This set of 22 olones did not contain any done making 
more than 2.0 lOg^u U / m l  (lower titres were not looked at).
The oontrast between these two sets of olones cannot be 
explained though culture conditions varied between the two - the 
former being buffered with bicarbonate and COg and the latter with 
hopes.
It is possible that the stage in the cell cycle is important 
for interferon production. Cell synchronisation would answer this 
question although only partial synchronisation of lymphoblastoid 
cell lines oan be achieved ( Zielke and Littlefield 1972 )»

Figure 7
Naraalwa c l o n e s  — m o r p h o lo g y .
N am alu a  c e l l s  a f t e r  24 h o u r s  g r o w t h  i n  < 5 cm t i s s u e  c u l t u r e  
f l a s k B .  M a g n i f i c a t i o n  x  2 0 0 .
a )  P a r e n t  c e l l  l i n e .
b ,  c  and d )  T h r e e  c l o n e s  d e r i v e d  fro m  t h e  p a r e n t  l i n e .

lit • * .-.i? ' V •• . >
V- \ & - ' * ■  ' ' ' ■ ■■■“ '. • o W > : *
ve; dd-;.. ’ ^'i¿)p
••■ " « t i  ■,*ra. ••'IT, -■"*■■■.. :rv,:; >
' il r i. ¿“v. i
Vii
, f V ' -
: ? u & s  '%te*&\ •: m d S m .. X- -V ■ ¿*
W ' - w :  f e ? .




Figure 8.
Namalwa cells - growth rates.
Growth of clones from 0.5 x 10*7 ml over three days.
( o-o ) I'arent cell line.
( ) Clone 1.
( O -a ) Clone 2.
(■ -») Clone 3.
(* - A ) Clone 4.
Mean of two experiments with duplicate determinations
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D o u b le  th y m id in e  o r  o t h e r  in d u c e d  b l o c k s  c a n  c a u s e  p e r t u r b a t i o n s  
i n  c e l l u l a r  m e t a b o l is m  th u s  c o m p l i c a t i n g  th e  i n t e r p r e t a t i o n  o f  any 
r e s u l t s .  T h y m id in e  f o r  i n s t a n c e  i s  w e l l  known t o  c a u s e  t o x i c i t y  and 
e v e n  m u t a g e n e s is  i n  m am m alian  c e l l s  p r o b a b l y  a s  a  r e s u l t  o f  ch a n g e s  
c a u s e d  b y  t h y m id in e  i n  t h e  i n t r a c e l l u l a r  p o o l s  o f  th e  o t h e r  
d e o x y n u c l e o t i d e  t r i p h o p h a t e s  (  B r a d l e y  and S h a rk e y  1 9 7 8 , S a f f h i l l  
and A b b o t  1 9 7 9  ) .
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III. 5'-bromodeoxyuridine. It3 effects and mode of action.
5'-bromodeoxyuridine is an analogue of thymidine and is 
incorporated by most cells into cellular DNA in place of thymidine, 
when added exogenously. It is not known whether 5'-bromodeoxyuridine 
must be incorporated into DNA before its effects are manifest.
Certainly in neuroblastoma cells it seems that a non—DNA linked 
mechanism is indicated ( Schubert and Jacob 1970 )•
5'-bromodeoxyuridine has a specific effect in inhibiting 
particular stages of differentiation in several cell systems (for 
review see Rutter ¿t .al 1973 ). The effect involves both the inhibition 
of growth (to varying degrees) and the specific inhibition of the 
production of specialised proteins made in differentiating cells 
( Bischoff and Holtzer 1970, Coleman at .al 1970, Lasher and Kahn 
1970, Stellwagen and Tomkins 1970, 1971, Weintraub et. al 1972,
Davidson and Bick 1973, Walther e£ ¿1 1974, O'Brien and Stellwagen 
1977 and Dudits at al 1979 )• The effect is not simply due to a 
depression of RNA or protein synthesis, since many of these effects 
occur at concentrations less than that required to significantly 
inhibit such biosynthesis ( Stellwagen and Tomkins 1971, Weintraub 
et al 1972, Pictet et al 1974 and Dudits .et al 1979 )• Furthermore, 
the effect on tyrosine aminotransferase is rapid and independent 
of the normal steroid inducers. There is also a differential rats 
of inhibition of enzyme activities and some enzymes are not even 
affected ( Stellwagen and Tomkins 1971 and O'Brien and Stellwagen 
1977 )• The time of treatment with 5'-bromodeoxyuridine is very 
important. There is no effect on the development of haemoglobin 
synthesis in erythroblasts treated with 5'-bromodeoxyuridine after 
haemoglobin synthesis has started, whereas it is completely inhibited 
if 51-bromodeoxyuridine is given prior to differentiations. A 3-fold 
higher concentration given after differentiation still has no effect 
( Wientrsub et al 1972 ).
Paradoxically, 5'-bromodeoxyuridine can also increase the 
production of certain enzymes and proteins ( Koyama and Ono 1971,
1972, Bick and Soffer 1976, Biowas et al 1977 and Tovey et al 1977 ). 
Suoh increases can occur in the same cells where 5'-bromodeoxyuridine
i n h i b i t s  o t h e r  en zym es an d  d o e s  n o t  a f f e c t  o t h e r s  a t  a l l  (  O 'B r ie n  
and S t e l lw a g e n  1977 )•-
A l l  th e  e f f e c t s  a r e  c o m o l e t e l y  r e v e r s i b l e ,  i n d i c a t i n g  t h a t  
c e l l u l a r  dam age i s  s l i g h t  a t  th e  c o n c e n t r a t i o n s  u s e d .  I t  seem s 
u n l i k e l y  t h a t  t h e  m u t a g e n i c i t y  o f  5 ' - b r o m o d e o x y u r id in e  p la y s  
a  s i g n i f i c a n t  r o l e  in  i t s  s p e c i f i c  e f f e c t s ' ,  T he l e n g t h  o f  t im e  
r e q u i r e d  f o r  i n d u c t i o n  o r  i n h i b i t i o n  i s  v e r y  s h o r t  and t h e  c e l l s  
c a n  g ro w  f o r  many p o p u l a t i o n  d o u b l in g s  w it h  t h e i r  DNA t o t a l l y  
s u b s t i t u t e d  w i t h  5 ' - b r o m o d e o x y u r id in e  f o r  t h y m id in e  w it h o u t  any 
g r e a t  e f f e o t  ( D a v id s o n  and  B ic k  1974» B ic k  a n d  S o f f e r  1976 and 
K aufm an and D a v id s o n  1977 )•
Other effects of 5 *-bromodeoxyuridine are the reduction of the 
tumourigenicity and acquisition of contact inhibition ( Siliga and 
Bruce 1970 ) and effects on the cell surface ( Kilton and Mach 1977)» 
Large morphological changes, referred to as a general ’transformation’, 
can also occur ( Davidson and Horn 1974 )•
5*-bromodeoxyuridine is also known to induce ’C ’-type and other 
latent viruses ( Aaronson et al 1971» Hampar e_t _al 1971» Klement 
et al 1971» Lowy .et al 1971, Sugawara ¿t al 1972, Stewart et al 
1972a, 1972b and Teich et al 1973 ). The time course of this effect 
is longer than the others ( Hampar et al 1971» 1973, Lowy et al 
1971 and Sugawara et ¿1 1972 )r and seems to require incorporation 
of 5*—bromodeoxyuridine into DNA ( Teich et al 1973 ) and in the case 
of Spstein-Barr virus, the activation is S-phase specific ( Hampar 
et al 1973 )•• The induction occurs in every cell in Balb C mouse 
embroyo 3T3 cells as shown by cloning the cell population from 
single cells ( Aaronson et al 1971 )• The induction of the defective 
murine sarcoma virus (MSV) by 5 ’ -bromodeoxyuridine occurs in the 
absence of helper virus murine leukaemia virus (MLV) and without any
detectable MLV-specific antigen being formed ( Klement et al 1971 )» 
and therefore one cannot explain the high numbers of cells that 
are induced to form virus by the mutagenic action of 5’-bromodeoxy­
uridine. The chemically induced virus is antigenically different from 
MSV but the physical characteristics of the virus are similar to the 
MLV/MSV complex. The probable explanation of the effect of 5’-bromo- 
deoxyuridine in the rat cells used is that a rat C -type virus is 
induced by the treatment and that this C-type virus performs the
helper virus functions required for the defective MSV to replicate.
It is also possible, however, that 5'-bromodeoxyuridine treatment 
causes a mutation in the MSV genome or causes elimination of a 
specific repressor, such that the MSV could replicate. Thus it is 
possible that 5'-bromodeoxyuridine disrupts the normal regulatory 
mechanisms that suppress virus formation in latently infected cells.
It has been shown that the lac repressor binds with a 10—fold higher 
affinity to 5'-bromodeoryuridine-substituted lac operon DNA than 
unsubstituted lac operon DNA, whether or not the inducer of the lac 
gene, isopropylthiogalactoside, is present ( Lin and Riggs 1972 ).
They suggested that the consequent decrease in the transcription of 
the lac gene resulted not just from a reduction in template activity, 
but by increasing the affinity of chromosomal proteins which are 
regulated. Thus constituitive enzymes would be less sensitive to 
inhibition by 5'-bromodeoxyuridine and this seems to be the adse 
( Stellwagen and Tomkins 1971 )•
It may be that other modulators of gene expression have a similar 
mechanism. Examples of specific gene expression induced by seemingly 
non specific treatments are heat shock and treatment of certain cells 
with amino acid analogues. Specific patterns of new gene expression 
are seen following heat shock of polytene chromosomes in Drosophila 
cells ( Lewis et al 1975 )• Treatment of cells with amino acid analo­
gues or mild heat shock induces the synthesis of three proteins, 
which then dominate the bio-synthetic capacity of the cells ( Kelly 
and Schleisenger 1979 )•
Several studies have shown that 5'-bromodeoxyuridine substitution 
of DNA alters the template activity of chromatin ( Hill et, al. 1973, 
Kotzin and Baker 1972, Matsumoto et al 1975 and Lykkesfeldt and 
Anderson 1977 ), both in vitro and in vivo. Studies on chromatin in 
vitro have shown that the thermal stability of DNA is higher when 
the DNA is substituted with 5 '-bromodeoxyuridine. A condensation of the 
chromatin also occurs ( Lapeyre and Bekhor 1974 )► This may be 
aocounted for by an increased affinity of chromosomal proteins for 
the substituted DNA ( David, Gordon and Rutter 1974 )• There is 
evidence for this suggestion, both for histones and non-histone
proteins ( Gordon et al 1976 and Schwartz 1977 ), though the latter 
show a much greater selectivity towards substituted DNA than the 
histones. This is interpreted as a specific affinity of substituted 
DNA for certain chromosomal proteins ( Gordon et al^  1976 ).
Mutagenesis as a mode of action for 5,—bromodeoxyuridine has not 
however been ruled out entirely. The molecules of glucose-6-phosphate 
dehydrogenase (G6PdH) from 5'-6romodeoxyuridine treated hamster cells 
have an altered heat lability and a different affinity for the 
co-factor NADP compared to native enzyme. This altered population of 
molecules increases with increasing substitution of 5,-t>r°in°(ieoxy- 
uridine into cellular DNA over 300 population doublings ( Bick and 
Soffer 1976'). The enzyme normally shows two peaks of activity, the 
second of which increases relative to the first peak after 5,_6romo— 
deoxyuridine treatment. This suggests that this fraction is the heat 
labile fraction. It is possible that there could be two gene loci for 
G6PcLH. Then the alteration in enzyme activity could be accounted 
for a change in transcription. The interpretation placed upon 
the results by the authors was that 5'-bromodeoxyuridine causes base 
sequence changes in the DNA and thus alters the primary sequence of 
the protein, which consequently has altered the physical properties 
of the protein.
5'-bromodeoxyuridine and deoxythymidine both cause mutagenesis., 
They also inhibit the enzyme ribonucleotide reductase at certain 
concentrations ( Reichard, Canellakis and Canellakis 1961 and 
Meuth and Green 1974 )•- This enzyme catalyses the reduction of 
nucleotide diphosphates and deoxynucleotides. The action of 
deoxythymidine and 5'-bromodeoxyuridine preferentially affects the 
reduction of uridine and cytidine diphosphates. ( Moore and Hurlbert 
1966 and Bjursell and Reichard 1973 )• The mechanism appears to be 
allosteric ( Bjursell and Reichard 1973 )• The mutagenicity of 
deoxythymidine and 5'-bromodeoxyuridine could result from an altera^ 
tion of the intracellular nucleotide pools. Deoxythymidine and deoxy- 
cytidine are believed to act in this way ( Bradley and Sharkey 1978 
and Saffhill and Abbot 1979 )• Deoxythymidine and 5'-bromodeoxy­
uridine may act by starving the cell for deoxycytidine which results 
in the misincorporation of deoxythymidine (or 5'-br°moiieoxyuridine)
for deoxycytidine in cellular DNA ( Bradley and Sharkey 1978 and.
Kaufman Davidson 1978 ). However both deoxythymidine and 
5'-bromodeoxyuridine cause mutagenesis in the presence of high con­
centrations of deoxycytidine, so their action cannot result from the 
starvation of the cell for deoxycytidine ( Davidson and Kaufman 1978 ). 
The ability of deoxycytidine to reverse some of the effects of 
5’—bromodeoxyuridine has recently been shown to be dependent on the 
conversion of deoxycytidine to deoxythymidine. However, the inhibition 
of the effect of 5 ’-bromodeoxyuridine is not a result of changes in 
the substitution of 5’-bromodeoxyuridine for thymidine in cellular 
DNA ( Davidson and Kaufman 1977 and Kaufman and Davidson 1978 ). It 
seems more likely that mutagenesis is caused by alterations in the 
relative concentrations of the nucleotide triphosphates. It has been 
suggested that increases in the dTTP/dCTP ratio are mutagenetic, while 
changes in the dATP/dGTP ratio are merely toxic. The inhibitor for 
DNA synthesis, hydroxyurea, is known to change the latter ratio ( Bradley 
and Sharkey 1978 ). There are fluctuations in the levels of all the 
deoxynucleotides during the cell cycle, but studies on synchronised 
cells have shown that the dCTP pool changes are the only ones that 
closely correlate to the rate of DNA synthesis ( Bjursell and Reichard 
1973 and Skoog, Nordenskjold and Bjursell 1973 )»
Another possible role for 5'-bromodeoxyuridine induced mutagenesis 
is by the induction of error-prone DNA repair, or by increasing the 
frequency of error by DNA polymerase itself ( Kaufman and Davidson 
1978 ).
Interferon yields have been reported to be increased after 
pretreatment of various cells with 5'-bromodeoxyuridine prior to 
induction ( Tovey et al 1977 )- The following series of experiments 
seeks to provide information .on the mechanism of action of 
5'-bromodeoxyuridine in modulating the interferon system in Namalwa 
cells.
Results«
Firstly optimisation of the conditions for the induction of 
interferon using 5,“BrBBrd- pretreatment was investigated. Initially 
72 hours pretreatment was used prior to induction of Namalwa cells 
with Sendai virus in the absence of 5,_BrdUrd, as published ( Tovey 
et al 1977 )• A table consisting of two experiments made to optimise 
all the variables (Table 6) shows several points. Firstly 5'-3rdUrd 
is toxic to the cells since their growth is inhibited to greater 
extents according to the dose of 5,-Br,durd used (fig.9 and Table6A).
An increase in the yield of interferon from treated compared to 
untreated cells is also seen. The effects of cell density and 
quantity of inducer are unaltered by 5'-Br<lurd (compare Table 6B 
& G to fig.2 & Table l). Further experiments (Table 7) confirmed 
the optimal conditions to be 1.0 x 10^ cells/ml induced with 
100HA/l0^ cells in 2$ serum after pretreatment with 25ug/ml of 
5'—BrdUrd. No interferon is detected in the absence of induction.
It was found that a shorter period of nretreatment resulted in 
higher titres of interferon (Table 8). 48 hours pretreatment was 
chosen as giving the most consistent yields since 24 hours pre- 
treatment gave much lower titres in preliminary experiments (Table 8). 
This suggests that there is a lag period before 5,-BrdUrd can increase 
yields of interferon. Further experiments were done to investigate 
whether 5,-Br<iUrd needs to be incorporated into cellular DNA before 
interferon yields are increased.
Other analogues of thymidine that differ from 5'-BrdUrd only in 
the substitution of another halogen atom for bromine at the 5' 
position of the molecule were tested (fig.10). Cells from the same 
culture were pretreated for 72 hours with each analogue. The analogues 
other than 5'-BrdUrd are more toxic than 5*-BrdUrd and FdUrd 
inhibits all cell division (Table 9)» In the latter case most of 
the cells were still viable as judged by trypan blue exclusion.
The interferon yields produced after pretreatment and induction 
under the optimal conditions judged for 5'-BrdUrd are shown in (fig.10). 
CldUrd is as efficacious as 5'-BrdUrd while XdUrd and FdUrd are less 
active.FdUrd indeed depresses interferon yields. It is known that IdUrd 
isinoorporated less well into DNA as a thymidine analogue compared to 
5'-BrdUrd and FdUrd is not incorporated at all. Although this data
Table
Pretr 
(pj/ml 
A)
Table Legend.«
A) Variable concentration of 5 ,-BrdUrd. Induction done with 
100 HAU Sendai virus/lO^ cells, 10^ cells/ml and 2/ serum.
B) Variable cell density during pretreatment. Induction as A.
C) Variable Sendai virus concentration during induction.
Induction with 10^ cells/ml in 2/ serum.
D) Variable serum throughout. Induction with 10^ cells/ml 
and 100 HAU Sendai virus/10^ cells.
D)
80
n done with 
and 2% serum.
idnction as A.
ld u ction .
ä l l s /ml
Table 6. Optimisation of the conditions for
pre-treatment and induction of 
Namalwa cells for interferon.
Pretreatment 
(p f /m l  5VBrdUrd) 
A)
0
5
10
25
50
100
3)
25
C)
25
D)
25
Cell density 
(xlO^ cells/ml)
0-85
0 .80
0-79
0-77
0.68
0.63
cells/ml
0- 5xl06
1- 0 
2-0
5- 0
10-0
HA/ml
1-3
6- 5 
13
65
130,
485
1000
io serum
10
0.59
0 - 6 4
Interferon yield 
(log^ U/ml/lO^ cells)
2.9
3 -4
3.1
3.7
3.3
3.6
2-5
2.5
3.2
3.2
3.2
2-7
2.6
3.2
2.8
3.3 
3.2
0 0.70 3.7
1 8.70 4.1
2 0.77 3.7
5 0.88 2.9
) 0-99 3.2
ffi/rure 9.
The cytotoxicity of 5'-hromodeoxyuridine.
Cell density of Naraalwa cells (initially 5 x 10^ cells/ml) after 
7 2 hours in the presence of various concentrations of 
5'-hromodeoxyuridine.
Averages of four determinations
■ki. .
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Table 7. Yields of interferon from Namalwa cells.
The effect of 5’-bromodeoxyuridine.
Pretreatment* Cell density Serum Interferon yield log 10
(xlO^cells/ml) U/ml/lO6 cells
(ug/ml 51 —BrdUrd) % (1)** (2)**
25 1.0 1 3.7 2.5
2 2.5 2.7
25 2.0 1 2.3 2.8
2 2.2 3.0
50 1.0 1 2.4 2.6
2 2.8 2.D
50 2.0 1 2.4 2.9
2 2.0 2.0
* Pretreated (see methods) with 5'-BrdUrd for 72 hours before 
induction.
** (l) Induction with 100 HAU/lO^ cells of Sendai virus.
(2) Induction with 500 HAU/lO^ cells of Sendai virus.
\
Table 8« Optimisation of the time required, for 
pretreatment of Namalwa cells with
S’-bromodeoTyuridine.
A) Interferon Yields (log 10 U/ml/lO^ cells)
Pretreatment Pretreatment Time (hours)
(ug/ml 5,-BrdUrd)
24 24* 48 48** 72
0 2.2 3.8 4.2 3.8 3.7
5 2.0 4.8 4.4 3.7 4.3
10 2.8 4.7 4.7 3.8 4.4
25 2.2 4.6 4.7 3.7 4.4
50 2.7 5.0 4.3 3.0 4.8
100 2.8 4.5 4.1 4.1 4.6
B) Cell densities*** (xlO^ cells/ml)
Pretreatment Pretreatment Time (hours)
(ug/ml 5’-BrdUrd)
24 24* 48 48** 72
0 0-84 0-87 1.15 0-68 1.2
5 0.67 0.80 0.96 0.82 1.0
10 0.61 0.63 1.17 0.78 1.1
25 0.63 0.73 0.70 0.73 0.83
50 0.62 0.37 0.74 0.96 1.0
100 0 .5 1 0.67 0.45 0.85 0.62
* Cells grown 24 hours, then pretreated with 5’-BrdUrd
for 24 hours
** Cells grown 48 hours, then pretreated with 5’-BrdUrd
for 24 hours.
Prior to induction«
fiions of-
Figure 10
The e ffe c t  o f thymidine analogues on the interferon 
production from Namalwa c e l ls .
Interferon yields from Namalwa cells after 48 hours 
pretreatment with varying concentrations of 5,_BrdUrd (• 
CldUrd (0-0), IdUrd ( D - D )  or FdUrd (■-■).
Mean of two experiments(<lup|ic«t«
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Table 9. The effect of thymidine analogues on the 
growth of Hamalwa cells.
Cell densities (x 10^/ml)
Pretreatment
(ug/ml)
FdUrd CldUrd 5'—BrdUrd IdUrd
0 0-82 0.82 1.2 ND
5 0.50 0-62 1.0 0.87
10 0.49 0-62 1.1 0.73
25 0.55 0.63 0.83 0.78
50 0-56 0.54 1.0 0.69
100 0.44 0 .5 1 0.62 0.54
Mean of two experiments^duplicate. deA^rminahon*).
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indicates that incorporation of 5'-BrdUrd into DMA may he a pre­
requisite for increased interferon yields, it is still possible that 
other cellular sites with some structurally specific receptor(s) may 
be the target.
If the cells are pretreated with thymidine alone, (fig.11) 
there is no comparable increase in interferon yields to 5'-Br(iUrd 
pretreatment. Thymidine can be used to compete out the effect of 
5*-BrdUrd (fig.12). The higher the proportion of thymidine the 
greater the reduction of the effect of 5 ,_BrdUrd. It seems most 
probable that thymidine is competing for incorporation into DNA and 
thus depressing the quantity of 5 '-3rcLUrd j.n DNA.
Thymidine can also compete out acid precipitable incorporation 
of labelled 5,_BrdUrd (fig.13). The amount of erogenous thymidine 
incorporated varies little in the presence of variable amounts of 
5'-BrdUrd. This may reflect changes in the cellular ^ool size of 
available thymidine molecules in response to uptake of exogenous 
thymidine. This may also result from the differential rate of 
incorporation of 5'-BrdUrd to thymidine (fig.14). This may be the 
result or cause of the different pool sizes of the nucleotides, qualit­
atively indicated by the determination of the acid soluble radio­
activity. The technique of caesium chloride density gradient centri­
fugation was used to indicate whether cellular DNA was the site of 
action of 5’-BfdUrd. It was shown that about 50^ of the thymidine in 
oellular DNA was replaced by 5 ,_Br<lUrd when cells were cultured in the 
presence of 25ug/ml 5'-3rdUrd (fig.15).
When 5'-SrdUrd is added to saturation density cells, which grow 
only slowly, there is no increase in interferon yields comparable to 
that seen with the effect of 5*-BrdUrd on growing cells (Table 10)* 
Addition of deoxycytidine to the medium, should present the cytotoxic 
effect by correcting the deficiency in deoxycytidine resulting fronr 
5»_BrdDrd treatment (see introduction). A reversal of this cytotoxic 
effeott of 5,_BrdUrd does occur with deoxycytidine up to 48 hours ( Tablell) 
without any change in the enhanced interferon yields following 5'“Br<UJrd 
pretreatment (Table 10). Deoxycytidine had no effect on the yields 
of interferon produced in S'-BrdUrd treated saturation density cells 
(Table 12).
Figure 11.
The effect of thymidine on Namalva cells. 
The effect of thymidine on
a) interferon production in Namalwa cells.
pretreatment with ¡j'-BrdUrd.
( 0-0 ) pretreatment with thymidine.
b) growth of hamalwa cells.
( ) pretreatment with 5,_BrdUrd.
( o—o ) pretreatment with thymidine.
The mean of two determinations
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Figure 12.
The effect of thymidine competition on the stimulation 
of interferon in Namalwa cells by 5'“^rdlJrd.
5' -Brdlird as a percentage of the total concentration of 
additives (3l.4mM).
ieans of two determinations
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Fifpire 13.
The effect of thymidine comoetition on the untake of 
5'—bromodeoxyuridine hy Namalwa cells.
Namalwa cells label'ed with either 2.^0i/ml "’H-Brdbrd or 
3H—thymidine.
a) The incorporation of 3H-BrdUrd with increasing thymidine 
concentration ( ê-t ).
b) The incorporation of 3H—thymiaine with increasing
5’--BrdUrd concentration ( 0-0 ).
c) Comnarison of a) and b) with corrections for the 
specific activity of the radiolabels
3H-Brdlird ( •-• ).
3;i-thymia.ine ( 0-0 ).
Mtaoi of 3 n b  Wltk dufKcati cUVirr*,rahonS.
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The rate of incorporation of thymidine and 
5'-bromodeoxyuridine into ilamalwa cells, 
harnalwa cells labelled with either Brdllrd or
^H—thymidire.
The kinetics of incorporation of "'H-Brdird (.h-A) and 
H-thymidine (A-+)  into acid nrecioitable material and
acii soluble
( o-o ) from Namalwa cell 
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top of coll ------a
meniscus
marker DNA _____b
teat DNA
bottom of cell ------d
density of CsCl - 1.4010, marker SÌA - 1*7100. 
length. of oell - 1.4ea*
Hagnifioation of pilotograpb - ar-d _ 7-$y
Siatance of aample band.
__ \ m diat. of rotor oentrefrom oentre of rotation (rsj a
r - 5.71 ♦ 5.65 .
* 5-43
r2 - 45.57.
Similarly for marker r - 5*71 +
“ 5-43.
r i  m 41.09.
/>• - / a  ♦ 4.2w2 (r2 - r2 ) x IO-10 g/om3 
w2 - 2.123 x IO7 , 4.2w2 x IO-10 - 8*9166 x IO"3.
/°m my°m + 8.916& X  IO-3 (r2 - r2 )
/>s - 1-71 ♦ 8.9166 x IO"3 (45.57 - 41.09)
- 1.75i/oa3.
5.43.
magnification!
factor.
at 44,000 rpm.
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Similarly for Naraalwa SNA unsubstituted with 5,_BrdUrd. 
a — b » 5»6Çcm.
a — o = 5»15cm.
magnification factor =* 7.8/j^ = 5.57. 
ra2 - 44.02.
rm2 - 45.22.
/ a  - 1.6993.
/° 5'-BrdUrd = 1.75.
P  unsnbst. - 1.699*
using GC » /° -1.660 then the mole fraction of 5'-BrdUrd present
0.098
in cellular SNA - 0.15*
Since thymidine has a mole fraction of about 0.3 in 
unsubstituted SNA this suggests about 50$ of thymidine 
residues are replaced with 5'-BrdUrd.
Macromoleoular synthesis in treated, cells compared to untreated 
cells was studied by following the incorporation of labelled 
precursors, (uridine, methionine and thymidine), into acid 
précipitable material, in the presence and absence of 5 ,_BrdUrd.
Pig. 16a and b shows that uridine and methionine incorporation in 
Namalwa cells, whether infected or uninfected, is only slightly 
depressed in the presence of 5'-BrdUrd. However thymidine incorporar- 
tion is significantly inhibited (fig.16c).
The kinetics of interferon production with 5'-SrdUrd show that 
there is merely more interferon produced at any given time compared 
with untreated cells (fig.18). This contrasts with the changes in 
the kinetics of production in response to antimetabolites, referred 
to as superinduction. Also no Sendai virus appears to be made in treated 
cells, thus Sendai virus replication is not enhanced in the manner 
in which latent virus production is induced by 5'-BrdUrd.
Discussion.
The results show that pretreatment of Namalwa cells with the 
thymidine analogue 5'-Brdürd results in higher titres of interferon 
if the cells are induced with Sendai virus. This phenomena is not 
akin to * superinduction' as described for interferon in fibroblast 
cells as judged by the kinetics. Thymidine alone does not result in 
higher titres of interferon and it competes out the effect of 
bromodeoxyuridine. 5'-BrdUrd gives rise to toxicity in the cells.
This presumably occurs by alterations in the deoxynncleotide pools, 
particularly that of deoxycytidine, in the manner described for 
other systems (see introduction). SNA synthesis is inhibited by 
5'-BrdUrd and this may result from the pool changes. Deoxycytidine 
reverses the toxic effect to some extent without reversing the effect 
of 5’-BrdUrd on interferon titres. Thus it seems likely that 5*-BrdUrd 
is incorporated into DNA as a prerequisite for its effeot on interfer­
on production. It is incorporated in 50% of the DNA in place of 
thymidine by 48 hours. Thus if a single cell division had occurred 
(the doubling time being 30 hours) all the substitution would be 
in a single strand of DNA and thus represents total substitution.
This may be why 48 hours is the optimum time for pretreatment.
9&
Table 10. The effect of deoxycytidine on interferon 
yields in Namalwa cells.
Interferon Yield 
(log10U/ml/l06 cells) 
Growing Saturation
Prntreatment* d®**fyiM) cells density cells
5'-BrdUrd)
0 (0.92)***2.8 (1-7) 3.25
25 (0.75) 3-6 (1-7) 3.55
50 ND (1-5) 3.3
100 ND (1-8) 3.5
0 100 (0.85) 3.05 ND
25 10 (0.98) 3-6 ND
25 100 (0.80) 3.65 ND
25 500 (1.00) 3.35 ND
50 100 (0.93) 3.35 (1.5) 3.35
* 48 hours with one or both 5'-bromodeoxyuridine and
deoxyoytidine..
** Deoxycytidine.
*** Cell density prior to induction.
ND Not done.
rftans of -t'krec acnis .
fable 11 The effect of deoxycytidine on the toxcity 
of 5,-bromodeoxyuridine.
Cell density (x 10^/ml) 
Pretreatment
'  —B rdU rd (y0.g/ ml ) dC*fyiM )
0 0
0 0
25 0
25 0
25 10
25 100
25 100
25 500
0 100
0 500
Pretreatment time (hours
24 48 72
0.44 0.73 0.96
O .56 O.65 0.87
0.31 0.54 0.64
0.31 0.49 0.66
0.40 0.72 0.80
0.43 0.65 0.73
0.42 0.60 0.74
0.45 O.56 0.64
0.44 0.69 0.96
0.44 0.77 0.74
De oxycytidine.
\\ians of -Hired -u.pe.riment«.
»9$
Table 12. The e f f e c t  o f d e o x v cv tid in e  on in te r fe r o n
prod u ction  in  s ta t io n a ry  Namalwa c e l l s .
Pretreatm ent* In te r fe ro n  Y ie ld
BrdUrd (¿ig/  ml ) dC**fyiM) (lo g ^ U /m l/lO ^  c e l l s )
0 0 3 .5
o ’ 100 2 .9
Q 100 2.-8
25 0 3-1
25 0 3-2
50 0 3 .0
100 0 3.3
25 10 2.75
25 100 2.5
25 500 2 .6
50 100 3 .0 5
*  48 hour.
**  D eoxycy tid in e*
\Aeans dr +Kree «j^nrnente
The e f f e c t  o f  5 '-b rom od eoxyu rid in e  on c e l lu la r  
m acrom olecular s y n th e s is .
The in corp ora tion  o f  ^ S -m eth ion in e  a) ^H -urid ine b ) and 
% -th ym ia in e  c ) .
0 -0  Untreated TCA p r e c ip i t a t e .
Treated TCA p r e c ip i t a t e .
Untreated TCA s o lu b le .
A - A  Treated TCA s o lu b le .
In corp ora tion  determ ined r e la t iv e  to  the i n i t i a l  
determ ination  (=100fo).
Figure 16.
Mean o f  three determ in ation s
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Evidence to support DNA as the site of action are the following!
FdUrd behaves in a manner opposite to that of 5,_BrdUrd and is not 
incorporated into DNA. 5 ,_BrdUrd is not effective in non-growing cells. 
Labelled 5 ,_BrdUrd is also competed out of acid précipitable material 
(DNA) by thymidine as is the effect of 5 ,_BrdUrd.
The work presented in this section thus far represents my work 
with 5*-BrdUrd on Namalwa cells. These results are incorporated in 
a paper (see Appendix l) where they are paralleled by a study of 
5'-BrdUrd on fibroblast cells undertaken by Dr. T. K. Bradshaw.
It seems pertinent to briefly discuss these results since they in 
part support and in part modify the conclusions presented above.
The cells used for this work were a normal fibroblast line 
HFF and an SV40 transformed line of fibroblasts WI-26. 5,_BrdUrd had 
a similar, though smaller, effect on interferon production after 
induction of HFF cells but had no effect on the WI-26 line. 5'-BrdUrd 
was cytotoxic to both these lines but even when the toxicity was 
reversed using deoxycytidine, interferon titres were not increased 
in the WI-26 cells. 5'-BrdUrd, however, was found to be incorporated 
into both these cell types to a similar extent compared to Namalwa cells 
during the period required to attain oonfluency and maximal interferon 
titres. Thus it is suggested that more than just the incorporation 
of S'-E^dUrd into cellular DNA is required before there is a stimulation 
of interferon production. It should be noted, however, that the SV40 
transformed WI-26 line can only be induced with poly(rl).(rC) and not 
with virus, whereas this situation is reversed for Namalwa cells. The 
effect of 5,_BrdUrd on interferon production in HFF cells can be 
demonstrated regardless of the manner of induction (poly(rl).(rC),
NDV or superinduction). This suggests the action of 5’-BrdDrd is 
indépendant of the manner of induction. Thus the block preventing 
the 3V40-WI-26 line cannot be ascribed to differences in induction.
It is not known if some other action of 5'-BrdUrd is required to 
stimulate interferon production or whether its activity is determined 
by the host cell.
As far as the DNA linked part of the mechanism is determined 
for Namalwa cells, similar results are obtained for HFF cells.
Thymidine itself is not stimulatory and competes out the effect of 
5'-BrdUrd. In confluent HFF cells where DNA synthesis is depressed to 
low levels, 5 ,_3rdUrd has no effect on interferon production. This may 
reflect a low incorporation of 5'-Br<iurd into cellular DHA. Deoxy- 
cytidine reversed the growth inhibition due to 5 ,_BrdUrd without 
affecting the stimulation of interferon production. Thus similar 
conclusions to that present for Namalwa cells, can he drawn from this 
cell line. In addition it can he pointed out that a stimulation of 
interferon production after 5,_BrdUrd treatment occurred when HFF cells 
were superindueed* Thus it seems the mechanism of aotion of 5 *-BrdOrd 
is distinct from the actions of the antimetabolites used in super­
induction.
Possibly the mode of action of 5 ,_BrdUrd reflects the hypothesis 
put forward in the introduction whereby an alteration in the binding 
of chromosomal proteins occurs resulting in changes in cellular gene 
regulation. One would predict from this model that increased trans­
cription of the interferon gene results from 5 ’-BrdUrd treatment. 
Clearly the short time required for the effect precludes any mechanism 
based on the direct mutangenic effect of 5'—:BrdUrd, though changes in 
the deoxynucleotide pool sizes may occur and could be responsible for 
the inhibition of DNA synthesis and growth.
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17. Butyric acid - a modulator of gene expression.
The use of sodium butyrate as a control for the effects of 
dibutyryl-cyclic adenosine monophosphate (dcAMP) lead to the 
discovery of morphological and biochemical changes in mammalian 
cells by this agent alone. Some of these effects are similar to 
those caused by dcAMP and are attributed to cAMP as a general cell 
effector. Other effects sire unique to sodium butyrate ( Prasad and 
Sinha 1976 )• Only butyric acid and a few closely related short chain 
fatty acids are active.
HeLa cells treated with sodium butyrate show hugh morphological 
changes, including the formation of very long processes. Electron 
microscopy shows that the cell membranes remain intact and there is 
no change in the number of several cell organelles ( Deutsch at al 
1976 ). Actinomycin D and Cycloheximide inhibit the morphological 
changes including the formation of the processes, so protein synthesis 
seems to be required for their formation, but once formed very little 
biosynthetic activity is required to maintain them ( Ginsberg et al 
1973 and Henneberry and Fishman 1976 ). There are large increases in 
micro-filament bundles and cytochalasin B and colchicine - inhibitors 
of microfilament and microtubule formation respectively - inhibit 
process formation. Thus microfilament and microtubule arrangement may 
be required for process formation ( Ghosh fit al 1976 and Altenburg, Via 
and Steiner 1976 )• Cytochalasin B has been observed to inhibit protein 
synthesis and break down polyribosomes ( Koch and Gppermann 1975 )*■
Thus, like many inhibitors, cytochalasin B and colchicine are not 
specific enough to draw conclusive results from their use. This has 
not stopped speculation that sodium butyrate might specifically induce 
or alter the synthesis or activity of a microtubule assembly protein 
analogous to the tan protein isolated from porcine brain and identified 
in many cell cultures ( Henneberry and Fishman 1976 and Lockwood 1978 ). 
Mono dibutyryl cAMP also causes this type of morphological change in 
Chinese hamster ovary oells and microtubules are again implicated 
( Hsie and Rick 1971| Henneberry, Fishman and Freese 1975 )• Regulation 
of the intracellular calcium ion concentration by the use of a specific 
calcium ionophore, also suggests a role for caloium in these morpho-
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effector. Other effects are unique to sodium butyrate ( Prasad and 
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microscopy shows that the cell membranes remain intact and there is 
no change in the number of several cell organelles ( Beutsch et al 
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seems to be required for their formation, but once formed very little 
biosynthetic activity is required to maintain them ( Ginsberg et al 
1973 and Henneberry and Fishman 1976 ). There are large increases in 
micro—filament bundles and cytochalasin B and colchicine - inhibitors 
of microfilament and microtubule formation respectively - inhibit 
process formation. Thus microfilament and microtubule arrangement may 
be required for process formation ( Ghosh ¿t al 1976 and Altenburg, Via 
and Steiner 1976 ). Cytochalasin B has been observed to inhibit protein 
synthesis and break down polyribosomes ( Koch and Gppermann 1979 )-
Thus, like many inhibitors, cytochalasin B and colchicine are not 
specific enough to draw conclusive results from their use. This has 
not stopped speculation that sodium butyrate might specifically induce 
or alter the synthesis or activity of a microtubule assembly protein 
analogous to the tan protein isolated from porcine brain and identified 
in many cell cultures ( Henneberry and Fishman 1976 and Lockwood 1978 ). 
Mono dibutyryl cAMP also causes this type of morphological change in 
ohinese hamster ovary oells and microtubules are again implicated 
( Hsie and Rick 1971» Henneberry, Fishman and Freese 1975 )• Regulation 
of the intracellular calcium ion concentration by the use of a specifio 
calcium ionophore, also suggests a role for caloium in these morpho-
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logical changes ( Henneberry, Fishman and Freese 1975 )> especially 
since calcium has an apparent regulatory role in microtubule formation 
( Borisy et al 1974 and Gallin and Rosenthal 1974 ). Treatment of 
certain cells with sodium butyrate can enhance or depress the activity 
of several enzymes. Examples of enhanced activity are* tyrosine 
hydroxylase, choline acetyltransferase, acetylcholine-esterase, 
catechol-methyl transferase, adenylate cyclase, alkaline phosphatase, 
a 5'-nucleotidase and a specific siayl transferase. An inhibition of 
activity is seen for the glucose phosphorylating enzymes - glucokinase 
and hexokinase - tyrosine aminotransferase and melanin formation (see 
Prasad and Sinha 1976 for review). It has been concluded that only 
membrane bound enzymes are altered in activity, while those enzymes 
from other putative subcellular locations remain unaltered ( Beutsch 
et al 1976 ).
It seems that the increase in siayl transferase activity in HeLa 
cells is important in the morphological change seen ( Simmons at al 
1975 and- Henneberry and Fishman 1976 ). Butyrate also causes changes 
in the glycolipids of the cell membrane ( Simmons et, _al 1975 ) and 
an incorporation of sodium butyrate itself into the cell membrane 
causes a change in membrane configuration ( Deutsch et al 1975 )•
Thus it seems that the membrane may be an important site for the 
action of sodium butyrate.
The induction of two enzymes — alkaline phosphatase and siayl 
transferase - in HeLa cells shows different kinetics. Colcemid treat­
ment of HeLa cells in the presence of sodium butyrate can also decrease 
the activity of alkaline phosphatase but not of siayL transferase.
Thus it has been suggested that the two activities are altered by 
different mechanisms. The activity of siayi transferase may be 
governed at the level of transcription while the activity of alkaline 
phosphatase may be governed by its degree of phosphorylation ( Beutsch 
et al 1976 ). The induction of siay.l transferase is blocked by actino- 
mycin B and cyoloheximide, so new mBNA and protein synthesis are 
required supporting the theory that gene transcription may be altered 
in this case.
In HeLa cells sodium butyrate enhanoes the production of two 
hormones. The o£-subunit of human ohoronio gonadotrophin (HCG) but
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not the^-eubunit, which confers biological activity — is stimulated 
( Ghosh 1976, 1977» Ghosh et al 1977 and Tralka .et al 1979 )• Similarly 
human follicle stimulating hormone (FSH) production is increased 
( Ghosh 1977 )• Estradiol secretion is inhibited by contrast and 
progesterone and placental lactogen also inhibits DMA synthesis 
in HeLa cells. Growth inhibition has been reported in several cell 
lines and an inhibition of DNA synthesis and a cessation of cell 
division occurs in some of these ( Bombik and Burger 1973, Schneider 
1976, Hagopian et, al 1977 and Marks and Rifkind 1978 )~ The 
stimulation of HCG -subunit and FSH in HeLa cells can occur when 
inhibitors of DNA synthesis alone are used e.g. hydroxyurea ( Ghosh 
1977 and Ghosh at al 1977 )• FSH production was synergistically 
affected in the presence of both hydroxyurea and sodium butyrate.
Thus an inhibition of DNA synthesis of cell multiplication may be 
required for changes in gene expression. It is interesting to note 
in passing that the HeLa cell genome is depressed for both 
differentiated and oncofoetal protein expression by these agents.
Sodium butyrate, dimethylsulohoxide and other planar-polar 
molecules as inducers of differentiation.
The Friend erythroleukaeraia cell has been used as a model 
system for terminal differentiation. In culture, murine erythro- 
leukaemia cell (MELC) lines - derived from mouse spleen cells 
infected with the Friend virus complex, grow with a low rate of 
spontaneous differentiation, about 0.5$. In the presence of certain 
induoers a much greater proportion of the cells differentiate 
( Hawkins and Krantz 1975 )• This induced differentiation is very 
similar to the normal differentiation, but occurs in the absence 
of the normal regulatory hormone — erythropoeitin. The cells rarely 
oomplete differentiation, which is marked by the extrusion of the 
cell nucleus to give non-nuoleated cells. Different patterns of 
gene expression from normal erythropoeisis are also seen ( Kabat 
et al 1975 )• Markers for differentiation includes morphogenesis
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( Friend et al 1971 ) > accumulation of globin °C and /3 mRNA, and 
f t  -globin synthesis, increases in heme biosynthetic ensymes, changes 
in purine metabolism ( Reem and Friend 1975 )» production of red cell 
membrane proteins and a limited cell division capability ( Kabat jet al
1975 ).
Inducers of this differentiation include planar-polar compounds, 
like hexamethylene bisacetamide, purines or their derivatives, hemin, 
short chain fatty acids such as sodium butyrate, inhibitors of SNA 
or RNA synthesis and X- or UV-irradiation. Not all these compounds 
act in the same manner ( Gusella and Houseman 1976, Ross and Lautner
1976 and Nudel et al 1977a» 197Tb )• Variants can be isolated that 
are resistant to one or all the inducers while others can respond 
to only a few but not all inducers ( Harrison et al 1978 and Ohta 
1976 ). The selection of dimethyl sulphoxide (DMSO) resistant clones 
is enhanced by mutagenesis ( i.e. using alkylating agents). Some 
variants remain stable while others revert to the normal phenotype.
It is argued that these variants arise by mutation, in spite of
the fact that one alkylating agent, -ethyl-methyl-sulphonate -» does 
not give rise to variants and the reversion rate is very high. Most 
DMSO resistant variants are non-inducible by DMSO for all different­
iation markers, but two variants are inducible for the erythrocyte 
specific membrane protein, spectrin ( Harrison et, al 1978 ). This 
is an early marker for differentiation and shows that spectrin 
induction can be unooupled from other aspects of differentiation, 
such as globin synthesis. In no DMSO resistant variant has globin 
synthesis been decoupled from hemin synthesis, so there is no 
evidence for regulation at the level of translation. An inhibitor 
of translation can, however, be found in MELC lysates. This 
inhibitor has been identified as a protein kinase that specifically 
phosphorylates the initiation factor eIF-2 and prevents the formation 
of the initiation complex required for translation. This is similar 
to the situation found in oell lysates made from interferon treated 
oells, (see page 5). What function, if any, this inhibitor has in 
the intact oell is not known (see Marks and Rifkind 1976 p.436)•
One variant, whioh is resistant to induotion, can be treated with 
the inducer plus hemin and terminal differentiation will then
proceed. This suggests that the variant is deficient in hemin 
synthesis ( Harrison .et, al 1978 ).
Regulation at the level of transcription does occur. RNA 
synthesis during differentiation declines overall as early as 2 
hours after induction hut there is an increase in globin mRNA 
synthesis within 6-24 hours, depending on the inducer and culture 
conditions. Globin mRNA synthesis is detectable in isolated nuclei, 
taken from DMSO induced MELC cells, after only 5 minuteB. Transcrip­
tional activation is the most likely explanation, although post- 
transcriptional stability of the mRNA may be increased ( Orkin and 
Swerdlow 1977 )• The pattern of and /^-globin mRNA accumulation, 
however, differs depending on the inducer, /^-globin sequences in 
mRNA are detectable later than -globin sequences and occur at a 
lower frequency in butyric acid and hemin induced cells and possibly 
in DMSO induced cells. Different inducers give rise to different 
accumulation of the /^minor globin mRNA. The major and minor globin 
genes are closely linked and the protein sequence differs by only 
6-10 amino acids, yet hexamethylene bisacetamide and DMSO induced 
cells accumulate different amounts of the two mRNA's and correspond­
ingly the proteins. There is no evidenoe for any translational or 
post-translational regulation. In contrast butyric and proprionic 
acid induction gives rise to equal amounts of the major and /& minor 
globins^( Model at al 1977a and b ).
Following induction, haemoglobin synthesis reaches very high 
levels. About 0.5-1$ of the poly-A containing RNA(mRNA) on poly­
ribosomes is globin mRNA and up to 10$ of the soluble protein in 
the oell is haemoglobin representing about 25$ of the total cellular 
protein being synthesized ( Rabat s i  ¿1 1975 )•
The inducers have demonstrable effects on other cell types 
and oause a difference in oncogenicity ( Marks and Rifkind 1978 )•
The inducers have been shown to penetrate the oell membrane and 
when prevented from being taken up (e.g. by binding the inducer 
oovalently to glutathione), then differentiation is not induced 
( Levy s i  al 1975» Marks and Rifkind 1978 p.429 )• Induotion by 
DMSO is also oell oyole specific, the cells requiring a period of 
pre-treatment in 3 phase ( Levy ¿t ¿1 1975 ) • The evidenoe suggests
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that the planar-polar compounds that induce are flexible and have 
an optimal separation of 5-8 methylene groups between their polar 
groups. These inducers are also toxic to the cells but it is not 
known if this is related to their mode of action or an independent 
effect ( Marks and Hifkind 1978 ).
Effects on the structure of DMA.
Changes in both the structure of UNA and in the chromosomal 
proteins are observed in vitro and in vivo with the inducers DMSO, 
hexamethylene bisacetamide and butyric acid. The sedimentation co— 
effecient of the cellular DNA changes after induction, suggesting 
that some change in structure has taken place. Differences greater 
than 5°$ in the quantity of 6 non—histone chromosomal proteins, 2 
nucleoproteins and 3 cytoplasmic proteins are seen after DMSO treat­
ment of MELC cells ( Peterson and McConkey 1977 )• A new protein of 
25,000 molecular weight has also been observed in MELC cells after 
treatment with DMSO or hexamethylene bisacetamide. This protein 
is not found in resistant variants or uninduced cells. The protein 
has similar properties to histone HI, but is not structurally 
related ( Eeppel, Allet and Eisen 1977, 1979 )• Changes are seen in 
the histones isolated from butyrate treated cells. The most obvious 
changes are seen for histones H3 and H4. It has been suggested that 
these changes result from an increase in the aoetylation of the 
histones.
A large proportion of the histones appears to be totally 
aoetylated and pulse label experiments with *^C acetate support 
the idea that aoetylation is increased ( Hagopian et al 1977 )•
The mechanism of this increased acetylation appears to be an in­
hibition of the histone deaoetylase enzymes. There are many reviews 
on histone modifications, but the function of this post—translation­
al modification is still not de a r  ( Georgiev 1969, Stellwagen 1969, 
Hearst 1970, Johnston and Allfrey 1978 ). It does appear that 
aoetylated histones are preferentially assooiated with actively 
transcribing chromatin ( Berlowits and Pallota 1972, Oorosky at al 
1973, Levy-Wilson, Gsereset and MoCarthy 1977, Johnston and Allfrey 
1978 and Oberhauser et al 1978 ). There is a correlation between
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histone acetylation and DNA-dependent RNA synthesis and acetylation 
proceeds or accompanies increases in RNA polymerase activity and RNA 
synthesis ( Johnston and Allfrey 1978 ). Thus histone acetylation 
is considered an early event in derepression of genes and important 
for the control of transcription ( Ruiz-Carillo, Nangh and Allfrey 
1973 ) or chromatin assembly ( Louie, Candido and Dixon 1973 ), 
though it may not be the only mechanism for the stimulation of RNA 
synthesis. There are changes in the amounts and patterns of histone 
acetylation associated with gene activation in lymphocytes, gene 
suppression in granulocytes, viral transformation, during differ­
entiation and development, and after treatment of certain cells with 
steroid or peptide hormones or drugs ( Johnston and Allfrey 1978 ). 
Numerous studies show that histone acetylation alters DNA conform­
ation. Studies with reconstituted chromatin .in vitro support this 
and show changes in template activity ( Marushige 1976 and Wallace 
et al 1977 ).
Non—histone proteins are also involved in chromatin structure 
( Adolph £t _al_1977 ) and in gene regulation ( Chiu and Hnilica 
1976 )• Phosphorylated non-histones are particularly implicated. 
Phosphorylation of histones also occurs and is involved in alter­
ations of chromatin structure and function ( Johnston and Allfrey 
1978 ). In at least one case a cAMP dependant protein kinase 
catalyses the .in vitro phosphorylation of histone 2A at a specific 
serine ( Shyaprukov et al 1975 )• Since some of the butyrate induced, 
effects are mediated by oAMP, phosphorylation of chromosomal proteins 
is a possible mode of action, although there is no evidence to 
support this idea.
Work with non-erythroid systems show that DMSO can destabilise 
the thermostability of base-pairs and protein-DNA interactions in 
vitro ( Lapeyre and Bekhor 1974 )• Specific changes in the gene 
expression of B. ooli can be seen after treatment with DMSO, both 
in vivo and in vitro ( Nakanishi et al 1974 ). It seems likely that 
the patterns of gene expression seen are a result of the specificity 
of the ohromatin structure already present in the cell. One may 
consider the preoursor erythroid oell as 'pre-programmed' and 
normally required only a single signal to initiate differentiation.
n o
Since inducers of differentiation other than the normal erythrop— 
oeitin, do not mimic the normal differentiation entirely, it is 
possible that further alteration in the structure of the chromatin 
are brought about by the initial gene expression when induced by 
erythropoeitin. Thus there could be a cacade system as envisaged 
by Britten and Davidson (l969) which is believed to operate in cells 
responsive to steroid hormones.
Ill
Results.
The conditions used for induction of interferon using 
pretreatment with sodium butyrate were those of Dr. M. Johnston 
(personal communication) and presented in the methods section.
Butyric acid reversibly inhibits the growth of Namalwa cells and 
stimulates interferon production if the cells are pretreated for 
48 hours ( M. Johnston personal communication).
To investigate the effect of butyric acid one cannot take a 
direct approach such as can be done with the action of 5*—■BrdDrd in 
relation to substitution into DNA. Butyric acid is not incorporated 
into a single subcellular fraction ( M. Johnston personal communicat­
ion ). Thus the approach taken was to study the effects of butyric 
acid on cellular functions relatin® to its stimulation of interferon, 
in the hope of finding some temporal correlation.
As a preliminary study the requirement for pretreatment was 
studied to ascertain the period before which butyric acid has no effect. 
Pig. 17 shows a typical experiment. 48 hours pretreatment was used in 
all further experiments since the most consistent yields are obtained. 
The kinetics of interferon production following pretreatment with 
butyric acid were also studied. Pig. 18 shows such a preliminary exper­
iment. There is always more interferon produced by butyric acid treated 
cells compared to untreated cells at all times at which interferon is 
detectable in the medium.
To attempt to dissect the kinetics of interferon a study with 
inhibitors of protein and ribonucleic acid synthesis was undertaken 
(figs.19 and 20). The use of cycloheximide prevents protein synthesis 
and can be used to determine whether interferon production is confined 
to a particular period. All interferon titres were determined after 
24 hours incubation.with cycloheximide present for various periods, 
being present either for a continuous period or being reversed by 
washing out. Pretreatment with cycloheximide (fig.20) shows that 
interferon is made to a lesser extent the longer cycloheximide is 
present indicating that interferon that is not translated in a parti­
cular period oannot subsequently be translated, thus the inactivation 
of the messenger RNA which is implied by the kinetios cannot be
Firrure 17
The s t im u la tio n  o f  in te r fe r o n  y ie ld s  f o r  Namalwa c e l l s .
The s t im u la tio n  o f  in te r fe r o n  y ie ld s  from Namalwa c e l l s  
by sodium b u ty ra te . C e lls  tre a te d  w ith  ImM sodium 
bu tyrate  ( C -0 ) , u n treated  c e l l s  (• -• ) .
Ills.
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The kinetics of interferon production in Hamalwa cells.
Cells treated with ImM sodium butyrate for 48 hours ( 0-0 ). 
Cells treated with 25)ig/ml 5,—BrdUrd for 48 hours ( A - A ) .  
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Figure 19c
The effects of actinomycin D and cycloheximide on 
interferon production from Namalwa cells.
a) Cells treated at one hour intervals post-infection* with 
actinomycin 1) (ljig/ml) (.A-4i) or untreated (O-O).
h) Cells treated at one hour intervals post-infection with 
cycloheximide (5Cyig/ml) (a - a ) or untreated (•-•). 
Interferon yields determined after 24 hours, the inducer 
being Sendai, lOOHa/lO^ cells being added at time zero.
*e.g. 3 hour ooint with actinomycin D represents the interferon 
titre at 2 4 hours with actinomycin present for the period 
3 —2 4 hours post-infection.
One of three similar experiments.
I i  f  ' f • L i ' ,  k  ♦* , W-r ; ¿ 1£  - J - v - r  4> ih - N :  » .  : ,#«*..*
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Figure 20.
The e ffe cts  o f  cycloheximide on interferon production 
from Namalwa c e l ls .
a) Cells treated with cycloheximide (50)ig/ml) (A -A  ) or 
untreated ( 0 - 0  ) .
All c e l ls  were infected with 100IIAll/l0^ c e l ls  o f  Sendai virus 
at time zero. The cycloheximide was washed out (3x with PBS) of 
samples o f a stock culture at each hour post-in fection  and medium + 
Sendai replaced.
Interferon y ie ld s  determined after 24 hours.
h) Cells treated with cycloheximide (A - A ) or untreated ( 0-0 ) .
Cells were treated with cycloheximide (5<^ig/ml) for  two hour 
periods at intervals following infection  with 100HAU/l0^ c e l ls  o f 
Sendai virus. The cycloheximide was then removed by washing 
(3x with PBS) and medium + Sendai replaced. Untreated ce lls  were 
mock treated with RPMI 1640 medium + 2$ PBS and in fected with 
100HAU/l0^ c e l ls  o f Sendai virus, then washed and re-in fected  as 
per treated c e l ls .
I n t e r f e r o n  y i e l d s  d e te r m in e d  a f t e r  24 h o u r s .
One of three similar experiments.
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inhibited, and furthermore it does not appear to he altered by treat­
ment with butyric acid as the decline in proauction is parallel to 
the untreated case. If treatment is post induction, no change in the 
interferon produced by 24 hours occurs no matter at what time the 
cycloheximide is added (fig-20b). The effect of actinomycin D, which 
inhibits cellular RNA synthesis, cannot be reversed and therefore 
actinomycin D can only be used post induction. Actinomycin U inhibits 
interferon production only at early times (fig.19). Since the time 
courses of release of interferon in the presence of cycloheximide is 
similar to the release of interferon from untreated cells it seems 
that interferon is released soon after synthesis.
Thus it seems that the overall rate of interferon production is 
not altered by butyric acid treatment. Evidence for an increased level 
of transcription has been presented ( Morser et al 1979 )• The inter­
feron mRNA in butyric acid cells is present at higher levels, as 
judged by translation of poly A containing RNA extracts of whole cells 
or polysomes. Further it was shown that interferon synthesis declines 
after 9-10 hours because the interferon mRNA is found in association 
with polysomes at its maximal concentration at this time and at lower 
concentrations before and after this time. The effect of actinomycin D 
(fig.19) suggests that interferon mRNA is made maximally by about 5 
hours since addition of actinomycin D after this time has no effect 
on the interferon titres obtained.
Since this is clearly at odds with the data derived from measure­
ment of the interferon mRNA levels but in agreement with other data 
( Zoon et ¿1 1979 ) it is suggested that actinomycin D either has 
some secondary effect (apart from direct inhibition of RNA synthesis) 
or the effect of actinomycin D may be complicated by a processing 
step required in the formation of active interferon mRNA«
There is no change in the amount of Sendai virus produced after 
butyrate treatment of cells. Semliki Forest virus grows to similar 
extents whether the cells are treated with butyrate, 5'—bromodeoxy- 
uridine or are untreated (Table 13)« Little change in the effect of 
Sendai on cellular maoromoleoular synthesis is seen with butyrio acid 
(fig*2l)* The figures are quoted in percentages since butyric acid 
substantially depresses cellular macromoleoular synthesis (figs.22 
and 23).
Table 13 The e ffe c t  o f sodium butyrate and BrdUrd 
treatment on SJj'V growth»
11?
A). TCA precip itable  uridine corporation expressed as 
InfectedsMock in fected  ra tio .
Hours post infection*
Treatment 2-3 3-4 4-5 5-6 6-7 7-8 8-9 9-10
None 178 452 1085 432 492 442 349 276
BrdUrd 
(25 p-g/ral) 184 332 778 :L011 695 426 409 264
Sodium
Butryrate(lmM) 342 620 578 451 446 317 209 151
B.). TCA solubles determination
Hours post
Treatment 2—3 3-4 4-5
infection* 
5-6 6-7 7-8 8-9 9-10
None 62 56 84 68 140 25 63 83
BrdUrd 
(25 pg/ml) 74 68 74 87 107 86 95 84
Sodium
Butyrate(lmM) 68 111 105 85 120 133 102 90
Nam alwa c e l l s  i n f e c t e d  w i t h  20 p f u / c e l l  o f  SFV and 
s u b s e q u e n t ly  l a b e l l e d  w i t h  10 u c i / l O  c e l l s  o f  
^ H -u r id in e  f o r  1 h o u r .
A c t in o m y c im D  ( l  j i g /m l )  w as ad d ed  a t  t = 0 .
\4ta/u o(- mines’ wiH\ d u f  hade. dlh.rmino.bont.
The e ffe c t  o f sodium butyrate on ce llu lar 
macromolecular synthesis pont-in fection .
A ll c e lls  were in fected  with 100HAU/l0  ^ c e lls  o f Sendai virus.
Panel A gives the data for the incorporation o f '’ H-thymidine 
(? 50n C i/l0 0 ral) .
Panel B gives the data for the incorporation o f ^H-uridine 
(250jiCi/100ml).
a) Incorporation into TCA précipitable material
• -  • Butyrate treated c e lls .
0 - 0  Untreated c e lls .
b) Incorporation into TCA soluble material
A  -A  Butyrate treated c e lls .
-  A  Untreated c e lls .
Incorporation was determined as the percentage o f  the incorporation 
o f radiolabel into samples compared with the incorporation into the 
butyrate treated samoles taken at three hours post-in fection . 
Butyrate treated c e l ls  were treated with ImM sodium butyrate for  
48 hours prior to in fection .
Means o f 3 determinations.
Figure 21.
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Figure 23
TCA soluble determinations from radiolabel determinations 
o f  ce llu lar macromolecular synthesis.
a) thymidine.
b) uridine.
c )  methionine.
A - A Namalwa c e l ls  treated with ImM butyrate
0 - 0 Untreated c e l ls .
Mean of two or three determinations
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Protein synthesis is least affected being reduced to 60$ of normal.
DNA synthesis is largely inhibited, being reduced to a few percent of 
that in untreated cells. Overall it is suggested, as far as can be 
ascertained, that the viral infection is largely unaltered. There 
appears to be no change in the proteins made in butyrate treated cells 
compared to untreated cells. Thus it appears that induction is the 
same and that the subsequent interferon production is enhanced contrary 
to the general effect of butyric acid on cellular protein synthesis.
The inhibition of DNA synthesis is not unexpected considering 
that the cells do not divide in the presence of butyric acid. The 
residual DNA synthesis could result from DNA repair synthesis by 
repair enzymes. The DNA per cell was quantitated by microdensito— 
metry to determine whether distribution of DNA contents per cell was 
similar to untreated cells (fig.24)« It is clear from the figures that 
while untreated cells show a biphasic distribution of DNA contents/cell, 
this distribution has only one peak for treated cells. The densities 
measured represent qualitative measurements of the quantity of DNA per 
cell nucleus. Sven so it is clear that the second phase in untreated 
cells contains about twice the density of stain and therefore twice 
the quantity of DNA per cell. These cells therefore represent cells in 
G2 phase. Thus an untreated population contains cells in G1 phase 
(normal DNA content per cell), cells in G2 phase (twice normal DNA 
content per cell) plus some cells in S phase (cells containing DNA 
contents between one and two times normal DNA content, exclusive). Also 
before division oells can contain twice the DNA content of cells that 
are in G1 phase. The single peak of DNA contents/cell for the treated 
oells is indicative of cells in G1 phase. This 'freezing* of the cells 
in a single phase occurs relatively soon after addition of butyric 
M i d  (fig.25). Thus it seems that the growth inhibition of butyric 
acid is a result of an inhibition of the transition of the cells from 
G1 to S phase.
The possibility that butyrate treated cells may be smaller than 
untreated cells, indicated by attempts to determine the protein and 
DNA contents of cells (Table 14), was investigated further. Using a 
Coulter counter reproducible reduction in the cellular volume of 
butyrio acid treated cells compared to untreated cells (fig. 26) 
was shown. Interestingly, some of the cells treated with butyrio 
acid are smaller than the smallest untreated cell. This oould
Firure 24.
The D4A content o f Namalwa c e lls .
Determined by measurement o f re la tive  (Feulgen) stain 
o f individual c e l l  nuclei.
a) Untreated c e l ls
b) Treated ce lls  ( ImM sodium butyrate for
48 hours ) .

Fipure 25.
The DNA content o f  Namalwa c e lls .
Determinations o f the re lative  Feulgen stain o f 
individual c e l l  nuclei
a) 3 hours treatment (lmM sodium butyrate).
b) 6 hours treatment (lmM sodium butyrate).
c )  l 6 hours treatment (lmM sodium butyrate).
d) 24 hours treatment (lmM sodium butyrate).
e ) 32 hours treatment (lmM sodium butyrate).
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Table 14« Chemical determinations of the protein and 
DNA content of Namalwa cells.
Protein (pg/cell) DNA (p g /c e l l )
Untreated cells Butyrate treated 
cells *
Untreated cells Butyrate treated 
cells *
17.3 13.8 5.2 1.5
14.1 13.7 11.5 4.7
37 .6 23.0 13.3 3.9
36.0 14.0 14.4 5-9
Mean 26.3 16.2 ll.l 4.0
•Cells treated with ImM sodium butyrate for 48 hours.
9Figure 26.
The e ffe c t  of sodium butyrate on c e l l  size .
a) Namalwa ce lls  treated with lmK sodium butyrate
for  43 hours or untreated (C7-C7) and infected with 
lOOHAU/lO ce lls  o f Sendai virus for  2 hours (closed 
symbols) or uninfected (open symbols).
Cell density was counted in a Coulter counter at A=32 
C=1 using a 70um pore. The closed c irc le s  represent 
a 1 2 . ? 2um diameter latex bead standard and the plotted 
lines are cumulative data from succesive 0 . 1 ml samples 
of c e l lo  diluted 1:4 in Isopon. The channel number is 
related to the c e l l  size (assuming a spherical share)
-  see Methods page.
b) Namalwa ce lls  tre-ted  fo r  15 hours ( A - A )  or 32 hours 0  
with ImM sodium butyrate or untreated ( • - • ) .
» - • )
Peak and mean volume for  the ce lls  as derived from the traces 
in f ig  a) and b) are shown following f ig  b)*
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Peak Median Median
volume(ji^) volume(jf^) diameter (ji)
a) Untreated and
uninfected cells. 740 730^270 11-2-1.2
Butyrate treated 
(48 hours) and 
uninfected cells. 410 445-165 9.6^1.0
Untreated and 
infected (lOOHAU/lO6 
cells) cells. 66 5 765-300 11.4-1.2
Butyrate treated 
(48 hours) and 
infected (lOOHAU/lO^ 
cells) cells. 465 475-155 9.8^0-8
b) Butyrate treated 
(32 hours) and 
uninfected cells. 615 590-380 10.4-2.1
Butyrate treated 
(15 hours) and 
uninfected cells. 472 545-285 10.2^1.5
Untreated control. 760 870^370 11.9-1» 5
a) Calculated on a line
b) Calculated on a line
at 1.8 
at 4.0
relative density, 
relative density.
* asstiming a perfect spherical shape.
F ig  re  27.
Transmission electron microscopy of Namalwa c e lls .
a) Namalwa ce lls  treated with sodium butyrate (lmM, 48  hours) 
Magnification x 11,000.
b) Untreated Namalwa c e l ls .  Magnification x 11,000.
c) P articles  observed in a single infected c e l l  ( x 45,000 ).




re fle c t  a chance in morphology i . e .  a more filamentous state which 
would be recorded as a smaller volume by the Coulter counter whilst 
retaining the same surface area. Transmission electron  microscopy o f 
Cun did ’ n i s ;  r "o «'bar. r - •; r c ' \ v ,’ ,1  ^ aa.! no
strik ing chances in in trace llu lar  components ( f i g . 2 7 )* l.'o v ira l part­
ic le s  were r,resent in the sections o f infected c o l ls  studied with the 
possible exception o f a. single c e l l  ( f ig .2 7 ) (out o f a few hundred 
examined). These particles are about 2C0nm in diexieter but whether 
they represent Sendai virions or ¿¡pstein-Barr v ira l particles  or other 
particles was not determined further. The lack o f p a rtic les  in the 
majority o f c e l ls  suggest that i f  they are not a r t ifa o tu r l, then part­
ic le s  o f such low freruenc,y wou1 a be hard to study, dcanninj electron 
microscopy revealed no dramatic differences between treated and un­
treated c e l ls  in their surface morphology ( f i g . 2 8 ) .  However two pecul­
ations o f c e l ls  seem to be rrerent regardless of treatment. One type 
o f c e ll  has a smooth c e l l  membrane ( f i r . 2 8 a) and the other ar cars 
'ru ffled*  ( f ig .2 8 b ). The basis for this morphological difference is  
not knovm. C learly , though, butyric acid treatment does not s ig n if ic ­
antly a ffect c e l l  morphology; the c e l ls  are merely smaller. The fact 
that they are smaller than the smallest untreated c e l ls  suggest (hat 
ce llu la r  membrane properties coulu be altered, resu lting  in a changed 
distribution  o f  the plasma membrane. An indirect study o f the plasma 
membrane was undertaken by testing  the permeability o f  the c e lls  to 
rubidium—86. This ion is  taken up in the same manner as potassium.
B o th  th e  r a t e s  o f  i n f l u x  o f  t h i s  i o n  and th e  r a t e s  o f  e f f l u x ,  a f t e r  
a  p e r i o d  o f  1 . 5  h o u rs  p r e l a b e l l i n g ,  w ere  m easu red  a t  t im e s  b e tw e e n  
2 and 60 m in u te s  a f t e r  a d d i t i o n  o r  r e m o v a l o f  e x t r a c e l l u l a r  ru b id iu m  
(T a b le  15). The r e s u l t s  show  t h a t  u p ta k e  o f  ru b id iu m  is d e c r e a s e d  
a f t e r  t r e a t m e n t  w ith  b u t y r i c  a c i d  b u t  t h a t  th e  e f f l u x  r a t e  i s  u n a f f e c t e d .
HlscuBBion.
The r e s u l t s  show  t h a t  sod iu m  b u t y r a t e  a c t s  in  a  s i m i l a r  f a s h io n  
t o  5 '-B r o m o d e o x y u r id in e  a s  f a r  a s  th e  e f f e c t  on  th e  k i n e t i c s  o f  i n t e r ­
f e r o n  p r o d u c t i o n ,  i n h i b i t i n g  c e l l u l a r  g ro w th  and h a v in g  no e f f e c t  on 
th e  g row th  o f  b o t h  th e  in d u c in g  v i r u s  and a p e r m is s iv e  v i r u s ,  SM»
Figure 28
Scanning electron microscopy o f Namalwa c e l ls .
a) and b) represent a sample o f the two d iffering  morphological 
types o f Namalwa c e l l .  Magnification x 200,000 approx.
c ) and d) as above with c e l ls  treated with ImM sodium butyrate 
for  48 hours.
The photographs presented here were maue by Dr. J. Beesley (Dept, of 
Electron Microscopy, Wellcome Research Foundation Laboratories) using 
samples o f Namalwa c e l ls  prepared by myself.
,ng morphological 
X 200,000 approx.
Eodium butyrate
J. Beesley (Dept, of 
n Laboratories) using






i' . . ' . j  y  *• í . ? í •* •
1 3 6
T a b le  15« The e f f e c t  o f  n r e t r e a t m e n t  o f  Hamalwa c e l l s  
w i t h  so d iu m  b u t y r a t e  on  t h e  -p e r m e a b i l i t y  
t o  r u b id iu m .
8 6 -R u b id iu n r  ( l m i C i /n r l , l 8 0 p g  R b /m l on  2 3 / 7 / 7 ? ) »
R a te
In flux Treated c e l ls 2417cpm -15 / 3-0x10 moles/min
Untreated c e l ls 2766cpm 7» 2xl0- ^moles/mirr.
E fflux* Treated c e l ls 5» 3min- ^
V *
46 mins
Untreated c e l ls 6.2min ^ 50  mins
The a b o v e  w as t h e  a v e r a g e  o f  3 e x p e r im e n t s  and  c o r r e c t e d  f o r  
d e c a y  ( t £  »  l 8 . 6 6 d ) ,  u s i n g  1 . 00x 1 0 ^  c e l l s / m l .
Efflux is  determined as the log^Q rate since the 
k in etics were exponential. *
** t i  is  the time fo r  the in trace llu lar  rubidium to decline
to h a lf of- the f i r s t  determination, obtained by extrapolation.
«W M ii
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However the similarities end here since sodium butyrate has no obvious 
site of action. Cells are arrested in G1 phase whereas cells treated 
with 5'-bromodeo:tyuridine still grow, albeit slowly. It is possible 
that cells only make interferon in G1 phase and thus virtually all 
the cells in a butyrate treated culture do, whereas only a proportion 
make interferon in an untreated culture. This seems unlikely consider­
ing the increase in interferon yields is generally about 10 fold, so 
the G1 phase would have to last only about 10$ of the cell cycle for 
this mechanism to be the sole basis for the increased yields. It has 
been shown elsewhere ( Morser _et al 1979 ) that the interferon mRHA 
levels detectable by oocyte assay are increased in butyrate treated 
cells. However the increase in quantity of the mRNA only accounts in 
part for the increase in interferon activity detected.
The mechanism of inhibition of DNA synthesis is not obvious but 
may result from changes in the binding- of chromosomal proteins in the 
presence of this lipophilic agent, be it direct or indirect. This has 
been proposed for other systems where DNA synthesis can also be inhib­
ited in vitro ( Hagopian _et al 1977 ). Acetylation of the histones may 
be involved (see introduction) and certainly histones are acetylated 
in the presence of butyric acid in Namalwa cells ( J. Morser personal 
communication ). Since many of the functions of chromosomal proteins 
remains unknown, this is a difficult area to study. However it is clear 
that these proteins play a role in the regulation of gene expression, 
so an alteration in these proteins offers a potential mechanism for 
changes in the expression of the interferon gene.
Other general mechanisms have been proposed for the action of 
butyrio acid. Sinoe it alters the properties of cell membranes, 
such an activity could result in alterations in cellular metabolism. 
Butyrio acid appears to alter membrane permeability in Namalwa cells 
but does not alter cellular morphology. Whether this altered 
permeability is significant as regards cellular gene expression 
remains to be demonstrated. It is perfectly possible that this 
effect is unrelated to the effeot on interferon expression or that 
it results from the inhibition of DNA synthesis.
Work with _in vitro systems derived from Namalwa oells could 
be an important step in elucidating the role of butyric acid 
directly on general oell expreseion.
CONCLUSION,
The work above shows that at the present time the only method 
of obtaining consistently high yields of interferon lies with 
treating Namalwa cells with suitable chemical treatments. The basis 
of the alteration in oellular macromolecular synthesis has not been 
uncovered. Since the effects of 5’—bromodeoxyuridine and sodium 
butyrate on all but interferon production are widely disparate it 
seems unlikely that alteration in a single mechanism in interferon 
production is indicated. Indeed it has not been ruled out that both 
chemicals act without altering rates of transcription or indeed that 
they act in more than one way to promote interferon production. The 
apparent complexity of the interferon system itself would indicate 
that several alterations in cellular functions might promote 
interferon production.
The effect on interferon production can be added to the many 
and varied activities of these two biologically active compounds. 
Several more trivial explanations of their activity have been ruled 
out —  they do not alter the activity of the inducer, the stimulation 
of interferon synthesis is not a result of a general stimulation of 
protein synthesis or an increase in cell size. There does not appear 
to be any subset of cells which are major interferon producers, thus 
it is unlikely that the treatments alter the relative proliferation 
of such putative subsets. The time of treatment is also critical - 
in the oase of 5'-Brd.Urd presumably the time to be substantially 
incorporated into cellular SNA, but for butyrio acid it is not known 
why 48 hours is the best time unless it is purely a synchronisation 
phenomenon. It is likely that during this time fundamental ohanges 
in oellular metabolism ocour, causing or resulting from changes in 
the structure and expression of cellular DNA-
An extension of this work into measuring the levels of trans­
cription of the interferon gene is indicated. This would lead to 
two types of study. Firstly, the purification of interferon messenger 
SNA might be possible leading to studies on the regulation of the
interferon system and possibly allowing genetic manipulation. Secondly, 
the action of the chemicals I have used at the level of the genetic 
material to selectively alter a single protein ( and perhaps a single 
gene ) might lead to information on the way they act to alter 
differentiation and thus on the mechanisms involved in differentiation
itself.
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